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Acute kidney injury (AKI) is a major risk factor for chronic kidney disease (CKD). For 
patients who recover from AKI, there is a 25% increase in the risk of CKD, and a mortality 
rate of up to 50% after 10 years. Nuclear factor kappa-B (NF-κB) is a family of 
transcription factors that regulates the transcription of many proteins that play a key role in 
inflammation. Inhibitor of IκB kinase (IKK) is directly upstream of NF-κB. My aim was to 
investigate a) the role of IKK in the progression of AKI to CKD, and b) whether its 
inhibition attenuates renal fibrosis. In this thesis I used a model of unilateral renal 
ischaemia-reperfusion injury with contralateral nephrectomy, to firstly map the acute time 
course of AKI. From the data generated from the time course, I decided to treat the animals 
at 24 h post reperfusion with the IKK inhibitor, IKK16, as i) this was at the peak of renal 
dysfunction (24 h post reperfusion), and ii) prior to the activation of NF-κB (48 h post 
reperfusion). The inhibition of IKK at 24 hours post reperfusion, as a delayed treatment, 
successfully attenuated renal dysfunction, NF-κB activation and renal structural damage. I 
subsequently increased the recovery time after ischaemia-reperfusion in my rat model to 28 
days to study the development of fibrosis post AKI. The inhibition of IKK at 24 hours post 
reperfusion successfully attenuated the development of fibrosis, formation of 
myofibroblasts, macrophage infiltration, the expression of pro-fibrotic markers and the 
deposition of extracellular matrix components at 28 days post reperfusion.  
In addition, the delayed inhibition of IKK at days 7-13 post unilateral ureteral obstruction 
in a rat model, successfully attenuated the development of fibrosis, formation of 
myofibroblasts, macrophage infiltration, the expression of pro-fibrotic markers and the 
deposition of extracellular matrix components. These data indicate that the activation of the 
IKK complex drives tubulointerstitial fibrosis, and suggests that the inhibition of IKK 
could be a useful pharmacological tool for the creation of therapies to combat AKI and the 
subsequent development of fibrosis, via the reduction of both inflammation and the 
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The Basic Structure and Function of the Kidney 
The kidneys are vital organs, performing multiple functions necessary for life. 
Located at the rear of the abdominal space, the kidneys are positioned either side of 
the vertebral column. The main function of the kidney is excreting metabolic waste 
products such as urea, uric acid and creatinine (Rang et al., 2007), alongside 
maintaining sodium (Na+), electrolyte levels, extracellular fluid volume and 
regulating the acid-base balance of the blood (Widmaier et al., 2007). In addition to 
these homeostatic roles, the kidneys produce the hormones erythropoietin (EPO), 
renin and vitamin D. The basic structure of both the kidney and its functional unit, 














Figure 1.1  
(A) The section of a mammalian kidney 
(B) The nephron of a kidney 






The nephron consists of two distinct sections; the first, named the renal corpuscle, 
consists of the Bowman’s capsule and the glomerulus, and is responsible for the 
filtration of the plasma (Figure 1.1B). The kidneys receive approximately 20% of 
the total cardiac output, which arrives at the renal corpuscle via the afferent 
arteriole, feeding into the glomerular capillaries. The high hydrostatic pressure 
created by the small diameter of the efferent arteriole causes ultrafiltration: the 
movement of small molecules such as water, amino acids, glucose, urea and sodium 
chloride (NaCl) from the blood into the Bowman’s capsule. This is called the 
filtrate, and is practically isotonic to the plasma (Widmaier et al., 2007). Larger 
molecules such as cells and proteins remain in the blood. The remainder of the 
blood (approximately 80%) then re-enters the circulation from the glomerulus via 
the efferent arteriole (Rang et al., 2007). 
From here, the filtrate then enters the second section of the nephron, the renal 
tubule. This section spans from the proximal convoluted tubule through to the 
collecting duct (Figure 1.1B) and it is here the filtrate is concentrated and finally 
excreted. The proximal tubule is divided into two portions – convoluted and 
straight, and from this is further subdivided into three further portions – S1, S2 and 
S3. S1 is present only in the convoluted portion, S2 is present in both convoluted 
and straight portions, and S3 in only the straight portion of the proximal tubule 
(Boron and Boulpaep, 2008). When the filtrate enters the proximal tubule, 
approximately two thirds of the NaCl in the tubular fluid is reabsorbed through Na+ 
transporters (Atthe et al., 2009). From here, the remainder of the fluid moves into 
the loop of Henlé; consisting of the pars recta, the descending thin limb, the 
ascending thin limb and the ascending thick limb. The high osmolality generated in 
loop of Henlé causes the reabsorption of water. On passing through the loop of 
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Henlé the fluid passes into the distal convoluted tubule, and then to the collecting 
duct system, which empties out into the renal pelvis. From here the now 
concentrated fluid, or urine, passes through the ureter and into the bladder, ready 
for excretion.  
 
Measurement of Renal Function 
Accurate measurement of renal function is paramount in both clinical and research 
settings. Renal function is measured by the glomerular filtration rate (GFR); 
described as the volume of fluid filtered from the glomerular capillaries into the 
Bowman’s capsule per unit time (Widmaier et al., 2007). An individual’s GFR is 
dependent on a multitude of factors, including age, race, body size and gender, and, 
therefore, no universal figure for a ‘normal’ GFR exists. However, the National 
Kidney Foundation Guidelines suggest that without kidney damage or any other 
underlying disease, the GFR of a healthy young adult is around ≥90mL/min/1.73m2 
(K/DOQI 2002). GFR is most accurately measured by the infusion of inulin, a 
polymer of fructose commonly found in plants. Inulin is an exogenous compound 
that is freely filtered and is neither secreted nor reabsorbed by the renal tubules, nor 
metabolised, so is the ‘ideal compound’ to measure the GFR. Despite this, inulin is 
seldom used to measure GFR in the clinical setting, as i) it is expensive to purify, ii) 
it is difficult to measure iii) its measurement is invasive to the patient and iv) its 
measurement is time consuming (Traynor et al., 2006). 
More commonly, creatinine is used clinically to measure renal function. Creatinine 
is an endogenous compound generated from the metabolism of the skeletal muscle 
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component creatine. Inulin and creatinine are both filtered at the glomerulus and do 
not undergo tubular reabsorption; but unlike inulin, creatinine undergoes a small 
amount of secretion (Widmaier et al., 2007). This proximal tubular secretion of 
creatinine causes the creatinine clearance (an indicator of glomerular function) to 
overestimate the GFR, but is close enough for clinical diagnosis (Traynor et al., 
2006). Despite this, the collection of urine over a period of hours is inconvenient to 
the patient, and this method may yield unreliable results. The estimated creatinine 
clearance is calculated as follows: 
The fractional excretion of Na+ (FENa+) is also used to measure renal function, and 
is defined as the percentage of the Na+ filtered by the kidney that is excreted. This 
is a highly efficient system, as only 0.4% of total Na+ filtered into the nephron is 
excreted in the urine (Boron and Boulpaep, 2008). 65% of Na+ is reabsorbed in the 
proximal tubule, initially by passive diffusion via the Na+/H+ antiporter and Na+ co-
transporters (such as the Na+/Glucose transporter). 25% of Na+ is reabsorbed in the 
thick ascending limb of the loop of Henlé via the Na+/H antiporter and the 
Na+K+2Cl- symporter, against its concentration gradient. Finally, the distal 
convoluted tubule is responsible for 5% of Na+ reabsorption by NaCl symporters, 
and the remaining 3% of Na+ is absorbed by the Na+ transporting cells in the 
medullary collecting ducts (Boron and Boulpaep, 2008). FENa+ is, therefore, an 




Renal failure is defined as the loss of renal function, where the kidneys are no 
longer able to effectively filter the blood of waste products. Acute kidney injury 
(AKI) and chronic kidney disease (CKD) are both manifestations of renal failure, 
formerly known as acute renal failure and chronic renal failure, respectively. Both 
AKI and CKD clinically present with a decrease in GFR and an increase in serum 
creatinine (SCr) concentration, albeit over different time frames. The causes and 
development of each disease are very different, and will be discussed subsequently. 
Severe AKI and CKD both lead to end stage renal disease (ESRD), which is 
defined as a GFR of <15ml/min/1.73m2 (K/DOQI 2002). Patients with ESRD 
possess suboptimal kidney function due to irreversible, permanent damage to the 
kidneys, and will require renal replacement therapies (RRT) to survive. Current 
RRTs include haemodialysis, peritoneal dialysis and renal transplantation.  
AKI and CKD may affect people at any time, however incidence increases 
proportionally with increasing age, with both AKI and CKD notably prevalent in 
the elderly (Winearls and Glassock, 2011). Currently both the average age of the 
population and life expectancies in developed countries are increasing, meaning 
RRTs are far more in demand than they were ten years ago. From 2001 to 2010, the 
number of patients receiving dialysis increased from 30,000 to 50,000 in the UK 
alone (Steenkamp et al., 2011). Currently, 90% of total patients on the organ 
register are waiting for a kidney (this is roughly 6000 people): the waiting time is 
around 1000 days (UK Renal Association, 2015), and in this time many patients 
die, even those receiving dialysis.  
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The exponential increase in patient numbers for RRTs is an ever-increasing burden 
on the National Health Service, due to the expense, length, and poor success rates 
of these treatments. This is a major reason why further pre-clinical and clinical 
studies investigating the mechanisms of these diseases, and the development of new 
therapeutic strategies, are vital.  
 
Acute Kidney Injury 
AKI is defined by the acute kidney injury network (AKIN) as ‘an abrupt (within 48 
h) reduction in kidney function currently defined as an absolute increase in SCr of 
more than or equal to 0.3 mg/dl (≥ 26.4 µmol/l), a percentage increase in SCr of 
more than or equal to 50% (1.5-fold from baseline), or a reduction in urine output 
(documented oliguria of less than 0.5 ml/kg per h for more than 6 h)’ (Mehta et al., 
2007). 
Approximately 5-7% of hospitalised patients present with AKI, and of this 5-7%, a 
further 60% will never regain full renal function (Uchino, 2006). On the intensive 
care unit, AKI is associated with a mortality rate of >50% (Ali et al., 2007), due to 
the development of ESRD (Uchino, 2006). AKI can occur secondary to clinical 
conditions such as sepsis (the most common cause of AKI), trauma/haemorrhage 
and from contrast agents (used in medical imaging e.g. magnetic resonance imaging 
(MRI)). AKI may also occur following cardiac bypass surgery or during warm 




AKI has 3 major aetiologies: 
1. Pre-renal azotaemia is the most common cause of AKI, characterised by 
reduced blood flow to the kidney due to low circulating blood volume, 
subsequently causing a decrease in GFR (e.g. sepsis, haemorrhage, congestive heart 
failure). Sufficient renal perfusion is required for the maintenance of a regular GFR. 
Pre-renal azotaemia can be volume responsive or volume non-responsive, in which 
the addition of i.v. fluids may or may not restore kidney perfusion (Sharfuddin and 
Molitoris, 2011).  
2. Post-renal azotaemia is caused by urinary obstruction e.g. kidney stones, 
catheters. Due to compensation of renal function from contralateral kidneys, 
significant renal failure will only occur if both kidneys are obstructed.  
3. Intrinsic azotaemia is caused by intrinsic damage to the kidney, and may affect 
one or more of the four structures of the kidney:  
• Tubules: Acute tubular necrosis (ATN) is a frequent cause of AKI, 
characterised by the death of epithelial cells that compose the tubules of the 
kidney. ATN may be caused by ischaemia or nephrotoxicity, causing an 
acute, usually reversible, loss of renal function (Nath and Norby, 2000). 
ATN occurs in three main stages, the initial, maintenance and recovery 
stages, which will be discussed in further detail later in the chapter.  
• Glomeruli: AKI may occur from acute glomerulonephritis, an inflammatory 
condition of the glomerulus, which may present as a primary disease or 
secondary to a systemic disease, such as systemic lupus erythematosus 
(Nowling and Gilkeson, 2011). 
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• Vascular system: Poor perfusion and a reduction in GFR from injury to 
renal vessels and capillaries may also cause AKI. This type of AKI is seen 
in severe cases of hypertension (roughly 1% of patients with hypertension) 
among various other conditions (Khanna and McCullough, 2003).  
• Interstitium: Acute interstitial nephritis may also cause AKI, from damage 
to the interstitial tissue. This is caused by bacterial or viral infections, or 
more commonly, allergies to certain antibiotics such as penicillin (Perazella 
and Markowitz, 2010). 
All three aetiologies of AKI lead to a reduction in effective perfusion to the kidney 
(Sharfuddin and Molitoris, 2011). Patients with AKI present with low GFR, a high 
FENa+, and oliguria (reduced urine output) (Atthe et al., 2009). Due to the 
reduction in GFR, the kidneys become unable to effectively filter blood of waste 
products, resulting in increased SCr and serum urea concentrations, and a 
consequent decrease in the urine creatinine concentration.  
Previously, AKI was classified by using the RIFLE criteria (Figure 1.2) abbreviated 
from Risk, Injury, Failure, Loss and End-stage Renal Disease: a method of clinical 
diagnosis depicting stages of AKI. The RIFLE classification relies on the delayed 
increase in SCr, at which point irreversible damage to the kidney may have already 
occurred (Van Biesen et al., 2006). This classification was, however, modified in 
2007, and AKI is now classified by the AKIN criteria. This criterion was devised 
without the ‘loss’ and ‘end-stage’ seen in the RIFLE classification, as these two 
stages are now deemed an outcome of AKI rather than a diagnosis. The AKIN is 



















Figure 1.2 The Risk Injury Failure Loss End stage renal disease (RIFLE) and Acute Kidney Injury Network 
(AKIN) classifications for acute kidney injury (AKI). The RIFLE classification, which is inclusive of 
creatinine, urine output and glomerular filtration measurements, has now been modified. Cr, Creatinine; GFR, 
Glomerular Filtration Rate; ARF, Acute Renal Failure; UO, Urine Output. Adapted from Cruz et al. (2009). 
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Pathophysiology of Ischaemic Acute Kidney Injury 
Ischaemia is the most common cause of AKI, caused by a reduction in effective 
perfusion to the kidney. As previously discussed, renal ischaemia manifests itself in 
the clinical setting as a primary condition and also secondary to conditions such as 
sepsis (Keir and Kellum, 2015). Pre-clinically, animal models of renal ischaemia-
reperfusion injury (IRI) are used to model AKI, by occluding the renal artery, vein 
and nerve (the renal pedicle). This is achieved by either bilateral or unilateral 
occlusion with contralateral nephrectomy (Skrypnyk et al., 2013). Experimental 
renal IRI commonly uses an ischaemic period between 30 to 60 min, longer periods 
of ischaemia resulting in more severe injury. 
The pathophysiology of ischaemic AKI is both complex and has yet to be fully 
understood, as it involves multiple pathways affecting many cell types and tissues 
(Figure 1.3). 
Figure 1.3 The pathophysiology of ischaemic acute kidney injury (AKI).  TGF-β1, transforming growth 
factor-β1; GFR, glomerular filtration rate; FENa+, fractional excretion of sodium. Adapted from 
Sharfuddin and Molitoris (2011). 
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The Ischaemic Period  
ATP depletion 
Ineffective perfusion to the kidney during ischaemia renders renal tubular epithelial 
cells unable to maintain sufficient adenosine triphosphate (ATP) production to 
perform basic cell processes (also known as the initiation phase of ATN). The renal 
tubular epithelium are covered in microvilli forming a ‘brush’ border on the luminal 
side of the tubule, increasing the surface area of these cells for specialised transport 
of water and ions.   
Lack of ATP may cause either sub-lethal (reversible) or lethal injury (irreversible) 
leading to epithelial and endothelial cytoskeletal disruption, or apoptosis and 
necrosis of cells, respectively (Figure 1.3) (Sharfuddin and Molitoris, 2011). These 
processes change both structure and function of the renal tubular epithelial cells, 
with the severity of ischaemic injury dictating the extent of the damage to these 
cells. Proximal tubule cells are the most sensitive to ischaemia, markedly in the S3 
segment, in the outer stripe of the medulla (Bonventre and Weinberg, 2003). Injury 
to S1 and S2 proximal tubule cells is usually reversible, however injury to the S3 
segment may result in cell death by apoptosis or necrosis (Venkatachalam et al., 
1978). 
Apoptosis and Necrosis 
Both apoptosis and necrosis are forms of cell death, or lethal cell injury, and have 
both been described in AKI (Padanilam, 2003). Apoptosis is described as 
programmed cell death, characterised by cell shrinkage, nuclear chromatin 
condensation, and the formation of apoptotic bodies. Apoptosis is an ATP-
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dependent process, limiting inflammation and damage to surrounding tissue, as the 
membrane of the cell stays intact throughout its breakdown, preventing leakage of 
cellular content (Sanz et al., 2008). Apoptosis may be activated via several 
pathways.  
On the other hand, necrotic cells are characterised by cytoplasmic swelling, 
irregular chromatin bundling, and eventual bursting of the plasma membrane 
causing cytoplasmic content to leak into the interstitium, resulting in inflammation 
and tissue damage (Lieberthal et al., 1998). Both of these processes have been 
previously described in AKI, with a dose-dependent relationship apparent between 
ischaemia time and the incidence of apoptosis and necrosis. In a rat IRI model, 
apoptosis occurs after only 15 min of ischaemia, with increasing incidence of 
apoptosis and of necrosis after longer ischaemia times (Schumer et al., 1992). This 
has also been demonstrated in vitro, where necrosis is the predominant method of 
cell death with severe ATP depletion (Wiegele et al., 1998).  
Cytoskeletal Alterations 
Sub-lethal injury caused by AKI is characterised by the loss of the apical brush 
border of the proximal tubular cells (Isaac et al., 2007), which occurs 
approximately 15 min after reperfusion of the kidney (Venkatachalam et al., 1978). 
ATP depletion causes the disruption of apical F-actin, causing a change in both the 
structure of the microvilli and the polarity of the cell (Kellerman and Bogusky, 
1992). The disruption of apical F-actin causes the formation of blebs, irregular 
bulges of the plasma membrane, which subsequently break off and are released into 
the tubular lumen. The loss of cell polarity may also be due to cytoskeletal 
alterations caused by the loss of expression of transmembrane integrin receptors. 
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Integrins facilitate cell to cell and cell to extracellular matrix (ECM) interactions, 
and during AKI, integrins relocate from the basolateral to the apical side of 
epithelial cells (Goligorsky et al., 1993). This movement causes detachment and 
clustering of the detached proximal tubular cells, causing tubular obstruction and 
contributing to the decrease in GFR (Goligorsky et al., 1993). When summated, 
blebs, brush border remnants and cellular debris all cause blockage of the tubule 
lumens – leading to a decrease, or halt, in GFR. 
Paracellular Permeability 
AKI also results in an increase in paracellular permeability due to the loss of tight 
junction proteins, such as ZO-1/ZO-2 (Tsukamoto and Nigam, 1997), causing back 
leak of the glomerular filtrate into the interstitium. Epithelial cells lose their 
attachments to the basement membrane due to the lack of ATP, causing mislocation 
of the basolateral Na+/K+ pumps. The redistribution of these pumps results in 
directional changes of both Na+ and water; causing Na+ to move back into the 
tubular lumen, therefore causing a high FENa+ (Bonventre and Weinberg, 2003), 
and consequently a concentrating problem. Thus, the FENa+ is a direct measure of 
tubular function, and is also used clinically for the differentiation between ATN 
(acute tubular necrosis) and pre-renal disease.  
The impaired reabsorption of Na+ in the proximal tubule cells contributes to the 
reduction in GFR via the activation of tubular glomerular feedback mechanisms 
(Navar and Mitchell, 1990). Tubuloglomerular feedback regulates GFR in normal 
renal health via the macula densa, which detects elevated NaCl concentration in the 
filtrate, activating purinergic signalling leading to afferent arteriole constriction, 
and therefore a decrease in GFR to normal levels (Carlstrom et al., 2015). 
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The Reperfusion Period 
The Effects of Continued Hypoxia 
On resolution of the ischaemic insult, the reintroduction of blood flow (reperfusion) 
into the kidney causes a further endothelial and parenchymal cell inflammatory 
response (known as the extension phase of ATN). Despite the re-introduction of 
blood flow post-ischaemia, continued hypoxia has been described due to reduced 
blood flow (Rabb et al., 1997). Under normal conditions, without AKI, the cortex, 
cortico-medullary junction (CMJ) and the outer medulla have partial pressures of 
oxygen (pO2) of 11.9, 4.1 and 7.9 mmHg respectively, as reported by Whitehouse 
and colleagues (2006) in a rat model (Whitehouse et al., 2006). Even under 
normoxic (and even more so under hypoxic) conditions, the kidneys possess lower 
oxygen levels in comparison to other organs (Safran et al., 2006). Both the 
continued hypoxia following an ischaemic event and inflammation is most 
pronounced in the CMJ post AKI. The CMJ exhibits a low basal pO2 under normal 
circumstances, making this region of the kidney more sensitive to injury caused by 
poor perfusion.  
The Vasculature 
Sublethal injury to tubular cells causes activation of the tubuloglomerular feedback 
mechanism, in turn causing an increase in renal vascular resistance (RVR) (Singh 
and Okusa, 2011). Vasoconstriction of the intrarenal vessels post AKI occurs to 
counter the decrease in renal perfusion rendering the kidneys unable to auto-
regulate blood flow, persisting up to one week post-injury (Conger and Schrier, 
1980). There are several other causes of increased RVR that may occur post AKI, 
including increased sympathetic nervous activity (Fujii et al., 2003), increased 
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formation of endothelin-1 (ET-1) (Firth et al., 1988), and primary damage to the 
renal vasculature. Alongside these, vasoconstriction is also caused by the decreased 
production and decreased response to vasodilators such as bradykinin, nitric oxide 
(NO) and acetylcholine (ACh). All of these factors impair vascular homeostasis, 
which underpins the early decrease in GFR seen in AKI. This is also accompanied 
by red blood cell ‘sludging’ (also known as Roleaux formation) in the 
microvasculature, where red blood cells retard and accumulate.  
Endothelial Dysfunction and Nitric Oxide Synthase 
Constitutively, endothelial cells regulate homeostatic processes such as vascular 
tone and permeability, however AKI causes dysregulation of the microvasculature 
promoting prolonged ischaemia, in turn causing further injury (Sutton et al., 2002). 
Endothelial damage causes a decrease in production of endothelial nitric oxide 
synthase (eNOS), an enzyme responsible for the production of NO, a cell signalling 
molecule with powerful vasodilatory properties (Noiri et al., 2001). This decrease 
in eNOS alongside an increase in ET-1 production further exacerbates 
vasoconstriction and platelet aggregation in the intrarenal vessels (Arfian et al., 
2012). 
Neutrophils in Acute Kidney Injury 
When damaged, the endothelium produces a plethora of pro-inflammatory and 
chemotactic cytokines such as tumour necrosis factor-α (TNF-α), monocyte 
chemotactic protein-1 (MCP-1) interleukin (IL)-8, IL-6, IL-1β and transforming 
growth factor-β (TGF-β), promoting neutrophil migration into the kidney tissue 
(Rabb et al., 1997). Neutrophils are the first inflammatory cells to infiltrate and 
accumulate in the tissue post IRI (Wu et al., 2007). The margination of neutrophils 
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into the tissue is facilitated by the upregulation of cell surface proteins such as P- 
and E- selectins on the endothelium, and the strong binding of cluster of 
differentiation molecule 11B (CD11b) on the neutrophils cell surface to upregulated 
intercellular adhesion molecule-1 (ICAM-1) on the endothelial cells (Molitoris and 
Marrs, 1999). This binding slows and eventually ceases the motion of the 
neutrophils allowing neutrophil diapedesis from the vascular lumen into the tissue 
towards the injured site. Infiltrating neutrophils exacerbate injury through free 
radical and eicosanoid production, enhancing the inflammatory response. Results 
from studies aimed at investigating the potential role of neutrophils in the 
pathophysiology of AKI have not provided a clear answer: Thornton et al. (1989) 
demonstrated neutrophil depletion with an antiserum conferred no renal protection 
compared to control animals subject to AKI (Thornton et al., 1989), whilst Kelly et 
al. (1996) have shown that mice deficient in ICAM-1, an intercellular adhesion 
molecule present on the endothelial membrane responsible for facilitating 
leukocyte-endothelial binding for transmigration of neutrophils into the tissues, 
were protected against renal IRI (Kelly et al., 1996). 
Macrophages in Acute Kidney Injury 
Macrophages are derived from monocytes, and produce cytokines such as IL-1, IL-
6 and TNF-α when activated. Macrophages also possess phagocytic capabilities. 
From 1 h post AKI, the number of macrophages in the kidney increases (Li et al., 
2008), most noticeably in the outer medulla (Ysebaert et al., 2000). Infiltration into 
the renal tissue is facilitated by the CX3CL1 receptor, expressed by injured 
endothelial cells (Oh et al., 2008), through interactions with CX3CL1 and CCR2 
expressed on the surface of both monocytes and macrophages (Ysebaert et al., 
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2000). They are also recruited via selectins on the endothelial cell surface post 
injury. Once recruited to the renal tissue, macrophages are involved in multiple 
inflammatory pathways, producing cytokines responsible for many effector 
functions such as the recruitment of neutrophils into the renal tissue (De Filippo et 
al., 2013). Ko et al. (2006) have demonstrated that liposomal clodronate depletion 
of monocytes and macrophages caused a significant reduction in both the structural 
and functional injury caused by AKI (Ko et al., 2008). Macrophages also play a 
pivotal role in renal repair (see below).  
Reactive Oxygen Species and Superoxide Dismutase 
Severe ATP depletion and the cessation of oxidative phosphorylation that occurs 
during ischaemia, causes epithelial cells to produce reactive oxygen species (ROS) 
(Weight et al., 1996). ROS include the most abundant superoxide anion (O2·-), the 
hydroxyl radical (·OH), and hydrogen peroxide (H2O2). O2·- is created as oxygen 
molecules accept a single electron from NADPH oxidase or xanthine (Nath and 
Norby, 2000). O2·- can consequentially be converted into H2O2 via dismutation by 
superoxide dismutaste (SOD) (Nath and Norby, 2000), and as O2·- is highly 
reactive, mammals, plants and bacteria have the ability to produce SOD as an anti-
oxidant defense mechanism. Mammals express three forms of SOD, all three of 
which are present in the kidney: SOD1 (cytoplasmic), SOD2 (mitochondrial) and 
SOD3 (extracellular) (Fukai and Ushio-Fukai, 2011). Increased SOD expression via 
recombinant adenovirus containing transgenes for human SOD successfully reduces 
damage associated with renal IRI such as tubular atrophy and inflammation when 
compared to control animals (Yin et al., 2001), and SOD1 knockout mice are 
associated with worse AKI than that of wild-type controls (Yamanobe et al., 2007). 
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The highly toxic ·OH ion is created from H2O2 and O2·-, catalysed by iron (Fe2+) 
ions (the Haber-Weiss reaction) or by Fe2+-facilitated decomposition of H2O2 (the 
Fenton reaction) (Zorov et al., 2014). ·OH has the ability to cause oxidative damage 
to DNA bases, despite its short half-life (Zorov et al., 2014). ROS may also be 
formed during the impairment of mitochondrial activity via the disruption of the 
electron transport chain (Gonzalez-Flecha and Boveris, 1995) (Cruthirds et al., 
2003) and higher levels of ROS have been measured in the mitochondria of rats 
subject to renal IRI (Gonzalez-Flecha and Boveris, 1995). Some infiltrating 
leukocytes demonstrate high levels of nicotinamide adenine dinucleotide phosphate 
(NADPH) enzyme activity (present on the plasma membrane of the leukocyte) and 
are therefore also a source of O2·- anions, contributing to further renal injury (Nath 
and Norby, 2000). 
Constitutively, ROS are involved in normal cell activities; however, at high 
concentrations (e.g. in AKI), these species damage lipid membranes, proteins and 
DNA, and cause destabilisation of cell-cell and cell-ECM adhesion via the 







Current Therapies for AKI  
AKI is a complex disorder, which is both costly and associated with a high 
mortality rate. Patients with AKI are usually anaemic, catabolic, and susceptible to 
sepsis and haemorrhage and have very little appetite. If untreated, serious 
complications involve cardiac arrest and even death. AKI sufferers require 
specialist treatment regardless of AKI severity. As of yet, there are no 
pharmacological therapies shown to safely ameliorate AKI as suggested by the UK 
Renal Association clinical practice guidelines (UK Renal Association, 2015), 
however there is an emphasis the prevention of AKI and slowing the progression of 
existing AKI because of this. Prevention methods include discontinuation of any 
diuretics, angiotensin converting enzyme (ACE) inhibitors, metformin and non-
steroidal anti-inflammatory drugs (NSAIDs) (Bilge et al., 2013). Other measures to 
slow the progression of AKI include dietary restriction of protein, Na+ and K+ and 
bicarbonate administration to counter acidosis (Turner et al., 2012). There is no 
current pharmacological cure for AKI, which is instead managed by the above 
methods. Research into AKI using animal models is required for a better 
understanding of the pathogenesis of AKI and for testing interventions as potential 






Chronic Kidney Disease and Renal Fibrosis  
CKD currently affects approximately 13-16% of the world’s adult population 
(Meguid El Nahas and Bello, 2005). It occurs secondary to such diseases such as 
diabetes mellitus, hypertension, and glomerulonephrosis. CKD is defined as a 
decline in GFR of <60 mL/min/17.3m2 for a period of three months or more, and 
unlike AKI, CKD is irreversible. CKD is divided into 5 stages according to 
severity, depending on the estimated GFR:  
 
ESRD is the common end point in both the AKIN and CKD classifications. Patients 
can live with CKD or AKI without requiring RRTs; however patients that further 
deteriorate to ESRD experience destruction of the kidney parenchyma and fibrosis 
of the kidney tissue (Liu, 2006). This pathology renders the kidneys unable to filter 
the blood efficiently, and from this point patients are unable to live without some 
 Figure 1.4 
The five stages of the chronic kidney disease (CKD) classification. CKD is defined as a GFR of <60 
mL/min/17.3m2 for a period of 3 months or more, and GFR of <15 mL/min/17.3m2 is classed as end-stage 
renal disease, where the patient will need some form of renal replacement therapy, such as haemodialysis 
or transplant.  Adapted From Levey et al. (2005). 
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form of RRT. However, patients with CKD exhibit a fivefold increase in the risk of 
mortality due to cardiovascular disease (Go et al., 2004), and may not reach ESRD.  
The progression from CKD to ESRD is characterised by renal fibrosis, an 
irreversible condition characterised by the excessive accumulation of ECM 
components and the alterations in the phenotype of both resident and infiltrating 
cell types (Chevalier et al., 2009).  Renal fibrosis is seen in almost all patients with 
ESRD, and currently there are no successful pharmacological treatments available 
to reverse fibrosis, or prevent its progression.  
 
Pathophysiology of Renal Fibrosis 
Initially, after injury caused by inflammation, wound healing is beneficial to 
restoring functionality of the kidney. However, there is a fine line between cellular 
repair and over-production of ECM components (Sharples, 2007). Over-production 
of the ECM causes renal fibrosis, which manifests itself in 4 stages: the cellular 
activation and injury phase (priming), the fibrogenic signalling phase (activation), 
the fibrogenic phase (execution) and the phase of renal destruction (progression). 
These four stages are not static however, and may occur at the same time (Eddy, 
2000). These stages will subsequently be discussed in more detail. It is impossible 
to highlight the key molecular pathway responsible for renal fibrosis, as the 
pathophysiology is complex and involves multiple cell types and tissues, all 
contributing to the activation, production and deposition of the ECM. 
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Priming 
Injury to the renal tissues, such as ischaemia, causes an inflammatory response 
which ‘primes’ the conditions of the kidney to fibrosis. Tubular cell damage causes 
the release of pro-inflammatory cytokines and chemokines such as MCP-1, in an 
attempt to self-repair (Wang et al., 2007). The release of such molecules creates a 
chemotactic gradient for immune cell infiltration from the systemic circulation into 
the interstitial space of the kidney. Such immune cells include monocytes, 
macrophages, T cells, leukocytes and mast cells (Duffield, 2010). The importance 
of the role of macrophages in CKD has been recently described (Kinsey, 2014). 
Infiltrating macrophages accumulate in both the glomerulus and the interstitial 
tissue, secreting a plethora of mediators influencing the development of renal 
fibrosis, such as growth factors (notably TGF-β), cytokines, enzymes, lipid 
mediators, matrix proteins, ROS, and many more upon recruitment and activation 
(Eddy, 2000). Interventions to deplete macrophages, such as inhibiting/blocking 
growth factors or chemotaxis have caused a reduction in glomerular inflammation 
and renal fibrosis (Ko et al., 2008). Macrophages have recently been classified into 
two subsets, M1 (classically activated) and M2 (alternatively activated). 
Macrophages recruited to the renal tissue post UUO are predominately M1 
macrophages (F4/80+ and CD301-), which are soon polarized to M2 macrophages 
(F4/80+ and CD301+), which in turn release high levels of TGF-β (Shen et al., 
2014a), suppressing inflammation of the kidney whilst promoting renal fibrosis 
(Anders and Ryu, 2011). Other inflammatory cell types such as dendritic cells, T 
cells and mast cells are involved in the initial inflammation of the kidney, but their 
role in the direct promotion of renal fibrosis is debatable. Unresolved renal 
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inflammation causes further damage to the tissues and a consequent positive 
feedback loop of chemotaxis and inflammation.  
Activation  
Alongside inflammatory mediators, resident and infiltrating cell types produce a 
plethora of growth factors during activation, such as TGF-β; a key mediator of 
fibrosis. TGF-β is activated by prolonged ischaemia, epithelial injury, angiotensin 
II and platelet-derived growth factor (PDGF) (Docherty et al., 2002). TGF-β1, the 
latent form of TGF-β, is produced by all renal resident cells, and is bound to 
latency-associated peptide (LAP), preventing receptor binding. On removal of LAP 
by latent TGF-β-binding protein, TGF-β is free to activate a downstream signalling 
pathway resulting in the activation of matrix-producing cells (Huang et al., 2008). It 
does so by binding the type II TGF-β receptor, a serine (Ser) threonine kinase, 
causing phosphorylation of the type I TGF-β receptor. Both type I and type II TGF-
β receptors form a hetero-tetrametic complex with TGF-β on the plasma membrane, 
which phosphorylates downstream receptor-associated Smads 2 and 3. Smad 2 and 
3 form a complex with Smad 4, and the resulting Smad complex translocates to the 
nucleus for gene transcription (Meng et al., 2015) (Figure 1.6). TGF-β has multiple 
functions in renal fibrosis, including the induction of collagen and fibronectin 
production, the inhibition of matrix metalloproteinases (therefore preventing ECM 
breakdown), inducing epithelial-mesenchymal transition (EMT) and endothelial-
mesenchymal transition (EndoMT) to the myofibroblast phenotype (Wu et al., 
2013), and can increase matrix production through the promotion of mesangial cell 
proliferation (López-Hernández and López-Novoa, 2012). TGF-β can also function 
	 42 
independently of the Smad pathways, e.g. through p38 and ERK (Derynck and 
Zhang, 2003). 
 
The principal matrix-producing cells involved in fibrosis are fibroblasts, located in 
the interstitial space of the kidney. Physiologically, they maintain the tissue 
architecture of the kidney, and produce a basal level of ECM to maintain matrix 
integrity (Kaissling and Le Hir, 2008). Fibrogenic factors such as TGF-β, PDGF, 
angiotensin II, and fibroblast growth factor (FGF) cause fibroblast activation and 
promote a change in phenotype from fibroblast to myofibroblast (Liu, 2011), and 
Figure 1.6 The TGF-β pathway. Stimuli such as ischaemia cause dissociation of TGF-β1 from latency-
associated peptide (LAP), facilitated by latent TGF-β-binding protein. TGF-β is then free to bind the 
type II TGF-β receptor causing phosphorylation of type I TGF-β receptor, causing the receptors to form 
a heterodimer. The TGF-β receptor complex phosphorylates Smad proteins 2 and 3, which in turn bind 
to Smad 4. The Smad complex then translocates to the nucleus to perform gene transcription of target 
genes. Adapted from Meng et al. (2015). 
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new expression of alpha-smooth muscle actin (α-SMA), vimentin and nestin 
(Sakairi et al., 2007). Myofibroblasts produce a higher volume of ECM components 
compared to fibroblasts, causing an imbalance in the homeostasis of collagen 
production. The origin of myofibroblasts is still under debate, however, LeBleu and 
colleagues estimated that 50% of myofibroblasts originate from proliferating 
resident renal fibroblasts, 35% from differentiating bone marrow, 10% from 
EndoMT and 5% from EMT, all contributing to the deposition of fibrotic tissue 
(LeBleu et al., 2013). 
Execution 
At this stage of the disease, myofibroblasts continually synthesise collagen I, 
collagen III and fibronectin (a 440kDa glycoprotein), contributing to the excess of 
ECM components. The kidney constitutively produces proteases and 
metalloproteases to degrade matrix components, however in the fibrotic state, 
protease inhibitors are synthesised preventing degradation of the ECM. Cai et al. 
(2008) have demonstrated that tissue inhibitor of metalloproteinase-1 (TIMP-1) 
deficient mice demonstrate more severe renal fibrosis in a model of UUO when 
compared to wild-type mice (Cai et al., 2008). Further to the inhibition of 
metalloproteases, the ECM is continually strengthened by cross-linking of proteins 
by transglutamination (Johnson et al., 1999), causing permanence and irreversibility 
of the ECM.  
Progression 
From hereon in, severe irreversible structural damage causes progressive renal 
insufficiency leading to ESRD. The continuous production of excessive ECM 
causes expansion of the interstitial space and consequent tubular cell death. 80% of 
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the kidney volume is composed of tubules, which are vital for the filtration and 
maintenance of blood composition (Eddy, 2000). The accumulation of matrix 
causes a gradual obstruction between tubular cells and peritubular capillaries, in 
turn causing tubular ischaemia and impaired oxygen diffusion vital for tubule 
function. Excess ECM also causes peritubular rarefaction and tubular hypoxia 
leading to apoptosis and necrosis of tubular cells (Marcussen, 2000). The gradual 
loss of renal parenchyma results in ESRD, and clinically, causing the kidneys to 
shrink due to the contraction of the fibrous scar tissue by myofibroblasts.  
 
Progression of Acute Kidney Injury to Chronic Kidney Disease 
 
Acute Kidney Injury as a Risk Factor for Chronic Kidney Disease 
 
Until recently, survivors of AKI were perceived to regain normal kidney structure 
and function. However, due to long-term follow-up studies post hospital discharge, 
this is now known to be untrue. Large population based studies have demonstrated 
a clear link between AKI and CKD (Hsu, 2012), where the severity of AKI predicts 
a patients outcome. Patients with severe AKI (especially dialysis-requiring AKI) 
have a higher probability of developing CKD than those with less severe AKI 
(Chawla et al., 2011), and an increased risk of cardiovascular mortality and 
proteinuria (Ishani et al., 2009). Patients experiencing multiple episodes of AKI are 
also at high risk of developing CKD, with each AKI episode doubling the risk 
factor for development of stage 4 CKD (Thakar et al., 2011).  The stress and 
damage caused by AKI predisposes patients to CKD; the pathophysiology of which 
is still poorly characterised pre-clinically. As previously described in this thesis, 
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AKI causes a series of inflammatory changes in the kidney, not limited to: tubular 
injury, tubular obstruction, vascular injury, endothelial cell activation and leukocyte 
recruitment. Following this, the kidneys attempt regenerative processes, where 




The Pathophysiology of the Progression of AKI to CKD 
 
Interstitial Inflammation and the Development of Fibrosis 
Inflammation post AKI involves infiltration of immune cells such as monocytes 
and neutrophils, as described above. The prolonged presence of these cells post 
AKI may aid the development of fibrosis, as shown by Forbes et al. (2001) who 
demonstrated macrophage accumulation was attenuated with the administration of 
an ET-1 antagonist, resulting in a decrease in collagen deposition (Forbes et al., 
2001). Other immune cells such as T cells may play a major role in CKD 
development post AKI (Chandraker et al., 1997), however, the mechanisms by 
which these cells contribute to the pathophysiology of AKI and their contribution to 









Endothelial Injury and Vascular Rarefaction 
 
Despite GFR returning to baseline post AKI, structural changes, more specifically 
in the vasculature, are still apparent. Basile et al. (2001) have described how in a rat 
model of renal IRI, 60 min of ischaemia followed by a 40 week reperfusion period 
caused a reduction in peritubular capillary density (around 30-50%) in the CMJ 
from 4 to 40 weeks after AKI (Basile et al., 2001). This was followed by the 
development of tubulointerstitial fibrosis at 40 weeks post AKI. In comparison to 
renal tubular epithelial cells, the endothelium has less affinity for regeneration. 
Vascular endothelial growth factor (VEGF) is a protein involved in the stimulation 
of angiogenesis, and is down-regulated post ischaemia (Basile et al., 2008). Lack of 
VEGF post AKI is a major contributor to vascular dropout seen in these animals 
(Basile et al., 2008). These data suggest that microvascular rarefaction causes 
further renal hypoxia, causing increased expression of pro-fibrotic molecules such 
as TGF-β (Fine et al., 1998), potentially driving AKI to CKD.  
 
The Role of the Cell Cycle in the Development of Chronic Kidney Disease from 
Acute Kidney Injury 
 
Yang et al. (2010) have recently described the role of cell cycle arrest in the 
development of renal fibrosis in mouse models of AKI and aristolochic acid 
induced nephropathy (AAN) (Yang et al., 2010). Arrest in G2/M phase of the cell 
cycle in proximal tubule cells in vivo and in vitro showed a strong correlation with 
the upregulation of profibrotic genes, and the subsequent development of fibrosis 
(Yang et al., 2010). c-JUN N-terminal kinases (JNK) are activated during G2/M 
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arrest, promoting upregulation of profibrotic genes and the production of collagen 
due to increased gene transcription of TGF-β1 and connective tissue growth factor 
(CTGF) (downstream of TGF-β1). Inhibition of JNK caused a reduction in the level 
of fibrosis seen in these animals (Yang et al., 2010). Epigenetic modifications may 
also contribute to CKD development, altering genes such as TNF and CCR2 
involved in renal inflammation post AKI. DNA methylations and histone 
modifications have already been described in both AKI (Zager and Johnson, 2009) 
and CKD (Wing et al., 2013). 
 
Chronic Kidney Disease as a Risk Factor for Acute Kidney Injury 
 
Conversely, CKD is also a risk factor for AKI. Episodes of AKI can be 
‘superimposed’ on pre-existing CKD, further accelerating the decrease in GFR and 
progression to ESRD (Okusa et al., 2009). The risk of AKI is proportional to the 
stage of CKD of the patient (Khosla et al., 2009): more advanced patients 
experience a higher number of episodes of AKI. It has been proposed that the stress 
and damage caused by one condition may predispose to the other, resulting in a 
positive feedback loop of continued deterioration in both structure and function of 
the kidney (Venkatachalam et al., 2010). The widening of the interstitial space by 
fibrosis contributes to reduced oxygen diffusion and therefore ischaemia, causing 






Current Therapies for Chronic Kidney Disease Development 
 
There is a large unmet need for therapies that both accelerate recovery from AKI 
and prevent or slow down the progression to CKD. Such therapies, however, can 
only be administered after diagnosis of AKI, when SCr increases are detected, 
usually 24 – 72 h post AKI. Multiple potential anti-fibrotic therapies have been 
studied in clinical trials for the treatment of CKD. Among these include anti-TGF-β 
antibodies to reduce excessive TGF-β signalling (Trachtman et al., 2011), ET-1 
antagonists (Wenzel et al., 2009) and phosphodiesterase inhibitors (Rodriguez-
Moran et al., 2006). Unfortunately, many have unpreventable side effects and there 




Nuclear factor-κB (NF-κB) is a nuclear transcription factor that regulates DNA 
transcription of many molecules involved in inflammatory pathways (Moynagh, 
2005). NF-κB comprises of a group of five proteins; p50 (NF-κB1/p105), p52 (NF-
κB2/p100), RelA (p65), RelB and c-Rel (Ghosh et al., 1998), which exist as homo- 
or hetero-dimers. All NF-κB dimers activate transcription with the exception of the 
p50/50 and p52/52 homodimers, which inhibit it. NF-κB is activated via two 
different pathways, the classical and the alternative.  
The classical pathway: The classical pathway causes activation of NF-κB through a 
variety of stimuli. These stimuli include pro-inflammatory cytokines such as IL-1β 
and TNF-α; receptors such as toll-like receptors (TLRs), antigen receptors and 
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viruses (Bonizzi and Karin, 2004). On detection by various cell surface receptors, 
such stimuli cause downstream signalling leading to activation of the IκB kinase 
(IKK) complex.  The IKK family consists of four different protein kinases, IKKα, 
IKKβ, IKKε and TBK1, all involved in the NF-κB activation pathway. IKKε and 
TBK1 however, are not involved in direct IκB phosphorylation leading to IκB 
degradation and will not be further discussed in this thesis. The IKK complex 
commonly consists of three subunits, IKKα, IKKβ and IKKγ (or NF-κB essential 
modulator (NEMO)) (Karin and Ben-Neriah, 2000). IKKα and IKKβ share an 
approximate 50% sequence homology, an N-terminal kinase domain, a 
dimerization domain and a C-terminal domain that binds IKKγ (or NEMO), a 
regulatory subunit. Upon activation, IKK causes phosphorylation of IκBα (at Ser 
residues 32 and 36), through IKKβ in an IKKγ-dependent manner (Schmid and 
Birbach, 2008). NF-κB is bound to IκBα in the cytoplasm in its inactive state. Upon 
phosphorylation of IκBα by the IKK subunits, IκBα is then polyubiquitinated (at 
Lysine residues 21 and 22) and degraded by the 26S proteasome (Karin and Ben-
Neriah, 2000). The NF-κB dimers are, therefore, released and subsequently 
translocate to the nucleus to commence gene transcription of a number of proteins 
including i) cytokines: IL-6, IL-1β, TNF-α; ii) chemokines: IL-8, MCP-1; iii) 
enzymes: inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2); and 
iv) adhesion molecules: ICAM-1, vascular cell adhesion molecule-1 (VCAM-1), E-
selectin (Bonizzi and Karin, 2004). Production of pro-inflammatory cytokines such 
as IL-8 and TNF-α cause a positive feedback loop resulting in further activation of 
NF-κB.  
The alternative pathway: The alternative NF-κB activation pathway is strictly 
dependent on IKKα (Senftleben et al., 2001). This pathway is only activated by 
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cytokines, and the only NF-κB proteins involved in this pathway are p52-RelB 
dimers. Examples of proteins produced include cytokines such as B-cell activating 
factor (BAFF), chemokines such as B lymphocyte chemoattractant (BLC) and 
secondary lymphoid-tissue chemokine (SLC), and lymphoid organogenesis genes 
(Bonizzi and Karin, 2004). For the purpose of this thesis, the alternative pathway 
will not be discussed any further. 
 
 
Figure 1.6 The classical NF-κB pathway. Stimuli such as pro-inflammatory cytokines or the activation of toll-like 
receptors (TLRs) promote a downstream signalling cascade activating inhibitor of IκB kinase (IKK), a 3 subunit 
kinase comprised of α, β and γ subunits. When activated, IKK phosphorylates Serine residues 32 and 26 on IκBα, 
causing the dissociation of NF-κB subunits, which translocate to the nucleus for gene transcription of inflammatory 
proteins. IL-1β, Interleukin-1β ; TNF-α , Tumour Necrosis Factor-α ; TLR, Toll-like Receptor; IKK, Iκ B kinase; 
mRNA, messenger ribonucleic acid; IL-6, Interleukin-6; IL-8, Interleukin-8; MCP-1, Monocyte Chemoattractant 
Protein-1; iNOS, inducible nitric oxide synthase; COX-2, Cyclooxygenase-2; ICAM-1, Intracellular Adhesion 
Molecule-1; VCAM-1, Vascular Cell Adhesion Molecule-1. Adapted from (Bonizzi and Karin, 2004). 
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NF-κB in Renal Disease 
 
The role of NF-κB in AKI has previously been described. Both its direct and 
indirect inhibition either prior to, or during, renal IRI has shown to attenuate AKI in 
animal models (Sanz et al., 2010), demonstrating the importance of this 
transcription factor and its involvement in AKI. Most notably, the specific 
inhibition of IKKβ via small interfering RNA (siRNA) before ischaemia reduces 
injury and/or aids recovery after unilateral renal IRI (Wan et al., 2011a). 
 
Currently, there are no effective anti-fibrotic therapies for preventing progression of 
CKD to ESRD; patients are limited to medication for symptoms such as anaemia, 
hypertension and hyperlipidaemia. The role of NF-κB in renal fibrosis has yet to be 
fully described; however the inhibition of IKKβ in both pulmonary (Inayama et al., 
2006) and hepatic (Wei et al., 2011) fibrosis has been proven efficacious, and 
overexpression of NF-κB in mouse hepatocyte cells causes fibrosis of the liver, an 
effect which is mediated by macrophages (Shen et al., 2014b). These data indicate 
the importance of NF-κB in fibrosis, and the potential for new therapies that target 














Currently, therapeutic interventions reported in the literature are administered 
before ischaemia (pre-treatment), after ischaemia, before reperfusion (pre-
reperfusion treatment), or up to 12 h post reperfusion (post IRI treatment). I have 
used two different animal models in this thesis:  
 
1. An in vivo rat model of renal IRI: Rats were subject to uninephrectomy and 
unilateral ischaemia (30 min) followed by different lengths of reperfusion 
(from 24 h to 28 days). 
 
2. An in vivo rat model of UUO: Rats were subject to right-hand ureteral 
ligation with a 14-day recovery period for the development of renal 
tubulointerstitial fibrosis.  
 
Using these models, the objectives of this thesis are:  
 
• To investigate the acute time course of renal injury and dysfunction in the 
rat model of renal IRI up to 72 h post reperfusion.  
• To investigate potential post reperfusion treatment strategies given during 
peak SCr values, at which time AKI is diagnosed in the clinical setting. 
More specifically, the inhibition of NF-κB activity via IKK inhibition, to 
ameliorate the renal injury and dysfunction associated with AKI.  
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• To investigate the degree of fibrosis developed in the rat model after 30 min 
ischaemia when the reperfusion period is extended up to 28 days of 
reperfusion.  
• To investigate whether the early amelioration of renal injury and 
dysfunction post IRI will successfully reduce or prevent the degree of 
fibrosis developed after an extended reperfusion period.  
• To investigate the inhibition of IKK in a rat model of UUO, after a 14 day 
recovery period.  
 
Overall, it is hoped that the findings of this study will elucidate the role of IKK in 


































The Delayed Administration of IKK16 
Reduces the Severity of Acute Kidney 





Previous studies have highlighted the benefit of the inhibition of IKK in IRI. In 
myocardial IRI, IKK inhibition up to 2 h post reperfusion reduces left ventricular 
infarct size and improves cardiac function when compared to vehicle treated 
animals (Moss et al., 2007). Further to this, IKK inhibition 1 h prior to cerebral IRI 
reduces ischaemic brain damage via reducing post ischaemic inflammation (Desai 
et al., 2010), and both deletion of IKKβ in hepatocytes, and the inhibition of IKKβ 
(in separate arms of the same study) conferred protection against hepatic IRI; 
reducing liver necrosis and inflammation when compared to wild-type animals 
(Luedde et al., 2005). More often than not, AKI in humans is associated with other 
conditions such as trauma, haemorrhage and septic shock, involving complications 
such as multiple organ failure. Sordi et al. (2015) have demonstrated that the 
inhibition of IKK with IKK16, given at resuscitation after haemorrhage, 
successfully reduced the renal, lung and liver injury associated with haemorrhage 
after 4 h of reperfusion in vivo. Inhibition of IKK also protected HK-2 cells from 
serum starvation in vitro (Sordi et al., 2015). Similarly, administration of IKK16 at 
1 h post onset of sepsis (caused by caecum ligation and puncture) attenuated renal 
dysfunction, cardiac dysfunction and hepatic injury (Coldewey et al., 2013).  
 
There are other interventions that reduce the severity of AKI, which also inhibit the 
activation of NF-κB. These include inhibitors of glycogen-synthase kinase-3β 
(GSK-3β) (Nelson and Cantley, 2010), EPO given 4 h post reperfusion (Patel et al., 
2012), ARA290, a non-erythropoietic analogue of EPO given 6 h post reperfusion 
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(Patel et al., 2012), and curcumin administered 12 h prior to IRI (Rogers et al., 
2012).  
 
IKK is directly upstream of NF-κB and has an important role in renal IRI, as its 
inhibition attenuates IRI-dependent changes in biochemical and histological 
parameters. Previous studies have, however, inhibited IKK pre-ischaemia or during 
early reperfusion. For instance, Wan et al. (2011a), attenuated renal IRI in rats 
using small interfering RNA (siRNA) targeting IKKβ, administered via the renal 
artery 48 h prior to IRI in vivo (Wan et al., 2011a). IKKβ siRNA attenuated IRI-
dependent increases in SCr and blood urea nitrogen, inhibited IKKβ gene 
expression, NF-κB binding to DNA, neutrophil gelatinase-associated lipocalin 
(NGAL) and IL-18 expression (Wan et al., 2011a). The same authors have 
demonstrated that treatment with siRNA targeting IKKβ to NRK-52E cells 72 h 
prior to cobalt chloride treatment (which mimics ischaemic AKI) attenuates cobalt 
chloride-dependent increases in both NGAL and IL-18 protein and mRNA levels, 
and also reduces the necrosis index in NRK52E cells treated with IKKβ siRNA 
(Wan et al., 2011b). Although Wan et al. (2011a, b) have shown that the inhibition 
of IKK is successful in ameliorating IRI in both in vivo and in vitro models, and 
therefore have highlighted the importance of the role of IKKβ in renal IRI, the 
translatability of this potential treatment strategy is limited to clinical situations 
such as transplantation and coronary artery bypass, where AKI is predictable 
(Rydén et al., 2014).  
Renal ischaemic pre-conditioning has also been shown to inhibit IKKβ, resulting in 
a reduction in SCr and tubulointerstitial injury score (Chen et al., 2009). These data 
suggest a detrimental role for the IKK complex in renal IRI.  
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In this study I have mapped the time course of AKI in a rat model of renal IRI, 
using both functional (serum urea, SCr, estimated creatinine clearance (eCCL), 
FENa+), structural (histology) and signalling (IKK phosphorylation, IκBα 
phosphorylation and NF-κB translocation) parameters to determine the best time 
point at which to treat the animals with a commercially available IKK inhibitor, 
IKK16, via a more clinically relevant route of administration (i.v.). Following this, 
I have looked at the effect of the inhibition of IKK on the above parameters 




Methods and Materials 
 
Animals received standard food and water ad libitum and all protocols followed in 
this study were approved by the local Animal Use and Care Committee in 
accordance with the derivatives of both the Home Office Guidance on the 
Operation of Animals (Scientific Procedures) Act 1986, published by Her Majesty’s 
Stationary Office (London, UK) and the Guide for the Care and Use of Laboratory 
Animals of the National Research Council. All results obtained from animals that 
died during the experiment were excluded from the data analysis and n numbers 






Renal Ischaemia-Reperfusion Injury  
Surgical Procedure and Quantification of Organ Injury/Dysfunction 
This study was carried out on 48 male Wistar rats (Charles River Ltd, Margate, 
UK) weighing between 240 – 290 g and receiving a standard diet and water ad 
libitum. Five animals were excluded from the study due to early mortality, a likely 
consequence of insufficient reperfusion of the kidney following renal IRI. Animals 
were anaesthetized using a ketamine (150 mg/kg) (Ketaset, Fort Dodge Animal 
Health Ltd., Southampton, UK) and xylazine (15 mg/kg) (Rompun, Bayer Plc, 
Berkshire, UK) mixture i.p. (1.5 ml/kg). The abdominal fur was shaved and the skin 
cleaned with 70 % alcohol (v/v). The animals were then placed on a homeothermic 
blanket set at 37°C (Harvard Apparatus Ltd., Kent, UK), and core body temperature 
was maintained at 35.5 – 36.5°C, monitored by a rectal thermometer. Animals 
received 0.1 mg/kg s.c. buprenorphine (0.1 ml/kg) (Vetergesic, Rekitt Benckiser 
Healthcare Ltd., Hull, UK) prior to commencement of surgery.  A mid-line 
laparotomy was then performed. The right renal pedicle (consisting of the renal 
artery, vein and nerve) was isolated and tied off using sterile 4-0 silk-braided suture 
(Pearsalls Ltd., Taunton, UK). The right kidney was then surgically removed. The 
left renal pedicle was isolated and clamped using a non-traumatic microvascular 
clamp (Fine Science Tools, California) at time 0. After 30 min of unilateral renal 
ischaemia, the clamp was removed to allow reperfusion.  (Sham animals underwent 
nephrectomy only). For reperfusion, the kidneys were observed for a further 5 min 
to ensure reflow, following which 8 ml/kg saline at 37oC was injected into the 
abdomen and all incisions were sutured in two layers (Ethicon Prolene 4-0, Johnson 
and Johnson, Livingstone, Scotland). Animals were then allowed to recover on the 
homeothermic blanket and placed into cages upon recovery. Twenty-four hours 
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prior to the end of the experiment, rats were placed into individual metabolic cages 
for the collection of urine and the subsequent determination of both eCCL and 
FENa+. At the end of the experiment, animals were anaethetised with a mixture of 
ketamine and xylazine (dose as before), and blood was taken by cardiac puncture 
into non-heparinized syringes and immediately decanted into 1.3 ml serum gel 
tubes (Sarstedt, Germany). The blood was centrifuged at 9900 g for 5 min to 
separate serum, then snap frozen in liquid nitrogen and stored at -80oC until further 
analysis. The left kidney was excised following removal of the heart. Half of the 
left kidney was snap frozen and stored at -80oC, and the other half was stored in 10 
% neutral buffered formalin for 48 h, then transferred to 70 % ethanol for storage.  
 
Experimental Design 
Acute Time Course 
Rats were randomly allocated to the following groups: (i) sham + vehicle (n=11); 
(ii) 24 h reperfusion (n=4); (iii) 48 h reperfusion + vehicle (n=8); and (v) 72 h 
reperfusion + vehicle (n=4). 
The Delayed Administration of IKK16, Late Intervention 
Rats were randomly allocated to the following groups: (i) sham + vehicle (n=11); 
(ii) IRI + vehicle (n=11); (iii) IRI + IKK16 0.1 mg/kg (n=5); (v) IRI + IKK16 0.3 
mg/kg (n=7); and IRI + IKK16 1.0 mg/kg (n=9). Rats were administered vehicle 
(10% dimethyl sulfoxide (DMSO)) or IKK16 24 h after the onset of reperfusion via 
the tail vein at a volume of 1 ml/kg. IKK16 was purchased from Tocris Bioscience 
(R&D systems Europe, Abingdon, UK), and the optimal dose estimated from 
	 60 
previous IC50 values (Waelchli et al., 2006). The dose response of IKK16 in renal 
IRI is displayed in the results section of this chapter.  
Measurement of biochemical parameters 
All biochemical markers in serum and urine were measured in a blinded fashion by 
a commercial veterinary testing laboratory (IDEXX Ltd, West Sussex, UK). The 
following parameters were measured:  
 
1. Serum urea levels (mmol/L) as a measurement of renal function 
2. SCr (µmol/L) as an indication of renal function and reduced GFR 
3. Urine flow (ml/min) as an indicator of urine production 
4. eCCL (ml/min) as an indicator of the GFR, calculated from the urine 
creatinine, urine flow, and SCr (see chapter I) 
5. FENa+ (%) the percentage of Na+ filtered by the kidneys that is excreted, 
and therefore an indicator of tubular function. The FENa+ is calculated from 
urine Na+ and creatinine and the serum Na+ and creatinine (see chapter I) 
 
Western Blot Analysis 
Western blots were carried out as previously described (Collino et al., 2006). Three 
to six separate experiments of Western blot analyses were performed for each 
marker and tissues were done separately for each Western blot experiment. Briefly, 
previously snap frozen rat kidney samples were homogenized and centrifuged at 
4,000 g for 5 min at 4°C. Supernatants were removed and centrifuged at 15,000 g at 
4°C for 40 min to obtain the cytosolic fraction. The pelleted nuclei were re-
suspended in extraction buffer. The suspensions were centrifuged at 15,000 g for 20 
min at 4°C. The resulting supernatants containing nuclear proteins were carefully 
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removed, and protein content was determined using a bicinchoninic acid (BCA) 
protein assay following the manufacturer’s directions (ThermoFisher Scientific, 
Massachusetts). Proteins were separated by 8 % Na+ dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a 
polyvinyldenedifluoride (PVDF) membrane, which was then incubated with a 
primary antibody; rabbit anti-total IκBα (1:1000 cat#4812 Cell Signalling 
Technologies, MA); mouse anti-pIκBα Ser32/36 (1:1000 cat#9246, Cell Signalling 
Technologies, MA); rabbit anti-total IKKα/β (1:200, cat#sc-7607, Santa Cruz 
Biotechnology, TX); rabbit anti-pIKKα/β Ser176/180 (1:1000 cat#2697, Cell 
Signalling Technologies, MA); rabbit anti-NF-κB p65 (1:1000 cat#8242, Cell 
Signalling Technologies, MA); rabbit-anti phospho eNOS Ser1177 (1:200 cat#9570, 
Cell Signalling Technologies, MA).  
 
Blots were then incubated with a secondary antibody conjugated with horseradish 
peroxidase (dilution 1:10000) and developed using the enhanced 
chemiluminescence (ECL) detection system. The immunoreactive bands were 
visualized by autoradiography. The membranes were stripped and incubated with β-
actin monoclonal antibody (1:5000) and subsequently with an anti-mouse antibody 
(1:10000 cat#7076, Cell Signalling Technologies, MA) to assess gel-loading 
homogeneity. Densitometric analysis of the bands was performed using Gel 
Pro®Analyzer 4.5, 2000 software (Media Cybernetics, Silver Spring, MD, USA) 
and optical density analysis was expressed as fold-increase versus the sham group. 
In the sham group, the immunoreactive bands of the gel were respectively 
measured and normalized against the first immunoreactive band (standard sham 
sample) and the results of all the bands belonging to the same group were expressed 
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as mean±SEM. This provides SEM for the sham group where a value of 1 is 
relative to the first immunoreactive band. The membranes were stripped and 
incubated with β-actin monoclonal antibody and subsequently with an anti-mouse 
antibody to assess gel-loading homogeneity. Relative band intensity was assessed 
and normalized against parallel β-actin expression. Each group was then adjusted 
against corresponding sham data to establish relative protein expression when 
compared to sham animals. 
 
Histological Evaluation and Scoring 
Kidneys were fixed in 10 % neutral buffered formalin for 48 h before being 
dehydrated with 70 % ethanol. Tissues were embedded in paraffin and sections 
were cut at 4 µm by a single technician in order to minimize variations in section 
thickness. The slides were deparaffinised with xylene, stained with haematoxylin 
and eosin (H&E) and viewed with Nanozoomer Digital Pathology Scanner 
(Hamamatsu Photonics K.K., Japan). Histological features such as glomerular 
shrinkage, tubular dilatation, basophilia, necrosis and luminal congestion were 
noted. Ten random images were taken per slide and quantified for total tissue 
surface area using ImageJ, as a marker of renal injury. 
 
Materials 
Unless otherwise stated, all compounds used in this study were purchased from 




All values described in the text and figures are expressed as mean±SEM for n 
observations. Each data point represents biochemical measurements obtained from 
up to 11 separate animals. Statistical analysis was carried out using GraphPad 
Prism 6.0b (GraphPad Software, San Diego, California, USA). Data without 
repeated measurements was assessed by one-way ANOVA followed by 
Bonferroni’s multiple-comparison post hoc test. A P value of less than 0.05 was 

























In order to understand the progression of AKI in rats, rats were monitored for 72 h 
following 30 min of unilateral renal ischaemia. Rats were subject to a right-hand 
nephrectomy and unilateral renal ischaemia at 0 h. Animals were then culled at 0 
(sham, no ischaemia), 24, 48 and 72 h post reperfusion. When compared to baseline 
(sham animals), rats that underwent 30 min of unilateral renal ischaemia developed 
significant renal (as measured by rises in serum urea (Figure 2.1A) and SCr (Figure 
2.1B)) and glomerular (as measured by a fall in eCCL (Figure 2.1C)) dysfunction at 
24 h of reperfusion, followed by a progressive recovery of renal and glomerular 











































Figure 2.1 The effect of 30 min ischaemia followed by different lengths of reperfusion (24, 48 or 72 h) 
on renal and glomerular function. IRI; ischaemia-reperfusion injury. Serum urea (A), serum creatinine 
(B) as indicators of renal function, and the estimated creatinine clearance (C) an estimate of the GFR, as 
a measure of glomerular function (in different set of animals for each timepoint). The peak of 
dysfunction in measured time points is 24 h after reperfusion. Sham + vehicle: n=11; 24 h post 
reperfusion: n=4; 48 h post reperfusion + vehicle: n=8; 72 h post reperfusion + vehicle: n=4. Data are 
presented as mean ± SEM of n observations, ★P<0.05 vs. sham + vehicle. 
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When compared to baseline (sham animals), rats that underwent 30 min of 
unilateral renal ischaemia developed significant tubular dysfunction (as measured 
by a rise in FENa+ (Figure 2.2)) at 24 h of reperfusion, followed by a progressive 
recovery in tubular function without intervention (Figure 2.2). These findings 






















Figure 2.2  The effect of 30 min ischaemia followed by different lengths of reperfusion (24, 48 or 72 h) 
on tubular function, measured by the fractional excretion of sodium (in different set of animals for each 
timepoint). The peak of dysfunction in measured time points is 24 h after reperfusion. IRI; ischaemia-
reperfusion injury. Sham + vehicle: n=11; 24 h post reperfusion: n=4; 48 h post reperfusion + vehicle: 
n=8; 72 h post reperfusion + vehicle: n=4. Data are presented as mean ± SEM of n observations, 
★P<0.05 vs. sham + vehicle. 
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Effect of Time on Activation of Intracellular Proteins post Ischaemia-
Reperfusion Injury in the Rat Kidney 
 
When compared to baseline (sham animals), kidneys removed (at 48 h of 
reperfusion) from rats that had been subjected to 30 min of unilateral renal 
ischaemia exhibited significant phosphorylation of Ser32/36 on IκBα (Figure 2.3A), 
as well as nuclear translocation of the NF-κB subunit p65 (Figure 2.3B). Rats 
culled at 24 and 72 h post reperfusion demonstrated no significant differences in the 
phosphorylation of Ser32/36 on IkBα or the p65 nucleus/cytosol ratio when 
compared to sham-operated rats (Figure 2.3).  
Figure 2.3 The effect of 30 min ischaemia followed by different lengths of reperfusion (24, 48 or 72 h) 
on the activation of IκBα and NF-κB. Activation of IκBα (A) was measured as phosphorylation of 
Ser32/36 on IκBα during the course of reperfusion. The activation of IκBα results in the activation of IKK 
and the subsequent nuclear translocation of the p65 subunit of NF-κB (B). Sham + vehicle: n=4; 24 h 
post reperfusion: n=4; 48 h post reperfusion: n=4; 72 h post reperfusion: n=4. IRI; ischaemia-
reperfusion injury. Densitometric analysis of the bands is expressed as relative optical density (OD) of 
IκBα phosphorylation at Ser32/36, corrected for the corresponding total IκBα content and normalised 
using the sham operated band. NF-κB nuclear translocation was evaluated by measuring NF-κB p65 
subunit expression in both cytosolic and nuclear fractions, and expressing the results as nucleus/cytosol 
ratio. Each immunoblot is from a single experiment. Data are presented as mean ± SEM of n 




I then measured the phosphorylation of IKK to study its activation. When compared 
to baseline (sham animals), kidneys removed (at 48 h of reperfusion) from rats that 
had been subjected to 30 min of unilateral renal ischaemia exhibited significant 
phosphorylation of Ser176/180 on IKKα/β and, hence, activation of the IKK complex 
(Figure 2.4). Rats culled at 72 h post reperfusion demonstrated no significant 
differences in the phosphorylation of Ser176/180 on IKKα/β when compared to sham-















Figure 2.4 The effect of 30 min ischaemia followed by different lengths of reperfusion (24, 48 or 72 h) 
on the activation of IKK. Activation of IKK was measured as phosphorylation of Ser176/180 on IKKα/β 
during the course of reperfusion. Sham + vehicle: n=4; 24 h post reperfusion: n=4; 48 h post 
reperfusion: n=4; 72 h post reperfusion: n=4. IRI; ischaemia-reperfusion injury. Densitometric analysis 
of the bands is expressed as relative optical density (OD) of IKKα/β phosphorylation at Ser176/180, 
corrected for the corresponding total IKKα/β content and normalised using the sham operated band. 
Each immunoblot is from a single experiment. Data are presented as mean ± SEM of n observations, 
★P<0.05 vs. sham + vehicle. Western blots performed by Massimo Collino & Fausto Chiazza. 
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When compared to baseline measurements (sham animals), kidneys removed from 
rats subjected to 30 min unilateral renal ischaemia culled at 48 h post reperfusion 
exhibited a significant increase in the phosphorylation of Ser1177 on eNOS when 























Figure 2.5 The effect of 30 min ischaemia followed by different lengths of reperfusion (24, 48 or 72 h) 
on the activation of eNOS, measured by the phosphorylation of Ser1177 during the course of reperfusion. 
Sham + vehicle: n=4; 24 h post reperfusion: n=4; 48 h post reperfusion: n=4; 72 h post reperfusion: 
n=4. IRI; ischaemia-reperfusion injury.  Densitometric analysis of the bands is expressed as relative 
optical density (OD) of eNOS phosphorylation at Ser1177, corrected for the corresponding total eNOS 
content and normalised using the sham operated band. Each immunoblot is from a single experiment.  
Data are presented as mean ± SEM of n observations, ★P<0.05 vs. sham + vehicle. Western blots 
performed by Massimo Collino & Fausto Chiazza. 
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Rationale for delayed treatment with an IKK inhibitor, IKK16 
 
Using these data, I decided to treat the animals at 24 h post reperfusion because:  
 
i) Renal dysfunction was greatest at 24 h post reperfusion (Figure 2.6A), 
as measured by SCr, most commonly used for the clinical diagnosis of 
AKI. 
ii) This timepoint (24 h) is prior to the activation of NF-κB (which peaks at 
48 h) (Figure 2.6B). 
 
 
Figure 2.6 The effect of 30 min ischaemia followed by different lengths of reperfusion (24, 48 or 72 h) 
on serum creatinine (A) a marker of renal function, and on the activation of NF-κB (B) as measured by 
the p65 nucleus/cytosol ratio. IRI; ischaemia-reperfusion injury. Sham + vehicle: n=4; 24 h post 
reperfusion: n=4; 48 h post reperfusion: n=8 (Figure A) n= 4 (Figure B); 72 h post reperfusion: n=4. 
Densitometric analysis of the bands is expressed as relative optical density (OD) of NF-κB p65 subunit 
expression in both cytosolic and nuclear fractions, and expressing the results as nucleus/cytosol ratio. 
Each immunoblot is from a single experiment. (B). Data are presented as mean ± SEM of n 
observations, ★P<0.05 vs. sham + vehicle. 
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The Effect of Late Inhibition of IKK on Renal, Glomerular and Tubular 
Function 
 
Having discovered that peak renal dysfunction of the kidney occurs at 24 h of 
reperfusion and the activation of IKK occurs at 48 h of reperfusion following 30 
min of unilateral renal ischaemia, IKK16 was administered 24 h after the onset of 
reperfusion (which lasted for a total of 48 h). Compared to rats subjected to renal 
IRI only, treatment of rats with IKK16 (1.0 mg/kg) at 24 h into reperfusion resulted 
in a significant and substantial attenuation of renal and glomerular and tubular 
dysfunction at 48 h post reperfusion, while lower doses of IKK16 (0.1 and 0.3 
mg/kg) had no significant effect (Figure 2.7). 
 
Figure 2.7 A dose response of the late administration of IKK16 (at 24 h into reperfusion) in a rat model of 
30 min of renal ischaemia followed by 48 h of reperfusion on markers of renal, glomerular and tubular 
function. Serum urea, serum creatinine were measured as indicators of renal function and estimated 
creatinine clearance were measured as an indicator of glomerular dysfunction, and fractional excretion of 
sodium as indicator of tubular dysfunction at 48 h of reperfusion. IRI; ischaemia-reperfusion injury. Sham + 
Vehicle: n=11, 10 % DMSO (1 ml/kg i.v.) 24 h into reperfusion; IRI + Vehicle: n=8, 10 % DMSO (1 ml/kg 
i.v.) 24 h into reperfusion; IRI + IKK16 0.1 mg/kg: n=5, 0.1 mg/kg IKK16 (1 ml/kg i.v.) 24 h into 
reperfusion; IRI + IKK16 0.3 mg/kg: n=7, 0.3 mg/kg IKK16 (1 ml/kg i.v.) 24 h into reperfusion; IRI + 
IKK16 1.0 mg/kg: n=9, 1.0 mg/kg IKK16 (1.0 ml/kg i.v.) 24 h into reperfusion. Data are presented as mean 




The delayed administration of 1.0 mg/kg IKK16 24 h post reperfusion significantly 
attenuated IRI-dependent increases in serum urea (Figure 2.8A) and SCr (Figure 
2.8B), and IRI-dependent decreases in the eCCL when compared to control animals 
administered vehicle, culled at 48 h post reperfusion (Figure 2.8C).  
 
 
Figure 2.8 The effect of late administration of IKK16 (at 24 h into reperfusion) in a rat model of 30 min 
of renal ischaemia followed by 48 h of reperfusion on markers of renal and glomerular function, and its 
comparison to the effect of 30 minutes ischaemia followed by different lengths of reperfusion (0, 24, 48 
and 72 h). IRI; ischaemia-reperfusion injury. Serum urea (A), and serum creatinine were measured as 
indicators of renal function (B) and estimated creatinine clearance (C) was measured as an indicator of 
glomerular function. Sham + vehicle: n=11; IRI + 24 h: n=4; IRI + 48 h + vehicle: n=8; IRI + 72 h + 
vehicle: n=4; IRI + 48 h + IKK16 1.0 mg/kg: n=9. Data are presented as mean ± SEM of n observations, 







The delayed administration of 1.0 mg/kg IKK16 24 h post reperfusion significantly 


























Figure 2.9 Effects of late administration of IKK16 (at 24 h into reperfusion) in a rat model of 30 min of 
renal ischaemia followed by 48 h of reperfusion on the fractional excretion of sodium, a measure of 
tubular function, and its comparison to the effect of 30 minutes ischaemia followed by different lengths 
of reperfusion (0, 24, 48 and 72 h). IRI; ischaemia-reperfusion injury. Sham + Vehicle: n=11; IRI + 24 
h: n=4; IRI + 48 h: n=8; IRI + 72 h: n=4; IRI + 48 h + IKK16 1.0 mg/kg: n=9. Data are presented as 
mean ± SEM of n observations, ★P<0.05 vs. sham + vehicle. 
	
	 74 
The Effect of Late Inhibition of IKK on the NF-κB Pathway in the Rat Kidney 
 
When compared with sham-vehicle rats, kidney homogenates prepared from rats 
that underwent 30 min of unilateral renal ischaemia and 48 h of reperfusion 
exhibited a significant increase in the phosphorylation of IκBα on Ser32/36 (Figure 
2.10A) and nuclear translocation of the p65 NF-κB subunit (Figure 2.10B). 
Interestingly, administration of 1.0 mg/kg IKK16 24 h after the onset of reperfusion 
significantly attenuated the increase in the phosphorylation of IκBα on Ser32/36 
(Figure 2.10A) and the subsequent nuclear translocation of the p65 NF-κB subunit 
(Figure 2.10B) caused by unilateral IRI.  
Figure 2.10 The effect of late administration of 1.0 mg/kg IKK16 (24 h into reperfusion) on ischaemia-
reperfusion injury on the activation of IκBα and NF-κB nuclear translocation at 48 h of reperfusion. 
Activation of IκBα (A) was measured as the phosphorylation of Ser32/36 on IκBα. The activation of IκBα 
results in nuclear translocation of the p65 subunit of NF-κB (B). Sham + vehicle: n=4; IRI + 48 h: n=4; 
IRI + 48 h + IKK16 1.0mg/kg: n=4. IRI; ischaemia-reperfusion injury. Densitometric analysis of the 
bands is expressed as relative optical density (OD) of IκBα phosphorylation at Ser32/36, corrected for the 
corresponding total IκBα content and normalised using the sham operated band, and NF-κB nuclear 
translocation was evaluated by measuring NF-κB p65 subunit expression in both cytosolic and nuclear 
fractions, and expressing the results as nucleus/cytosol ratio. Each immunoblot is from a single 
experiment. Data are presented as mean ± SEM of n observations, ★P<0.05 vs. sham + vehicle. Western 
blots performed by Massimo Collino & Fausto Chiazza. 
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To show that the inhibition of IKK by IKK16 was successful, the phosphorylation 
of IKK at Ser176/180 was measured to confirm its activation. When compared with 
sham-vehicle rats, kidney homogenates prepared from rats that underwent 30 min 
of unilateral renal ischaemia and 48 h of reperfusion exhibited a significant increase 
in the phosphorylation of IKKα/β at Ser176/180 (Figure 2.11). The administration of 
1.0 mg/kg IKK16 24 h after the onset of reperfusion significantly attenuated the 













Figure 2.11 The effect of late administration of 1.0 mg/kg IKK16 (24 h into reperfusion) on ischaemia-
reperfusion injury on the activation of IKKα/β at 48 h of reperfusion. Activation of IKKα/β was 
measured as the phosphorylation of Ser176/180 on IKKα/β. The activation of IKKα/β results in nuclear 
translocation of the p65 subunit of NF-κB. Sham + vehicle: n=4; IRI + 48 h: n=4; IRI + 48 h + IKK16 
1.0mg/kg: n=4. IRI; ischaemia-reperfusion injury. Densitometric analysis of the bands is expressed as 
relative optical density (OD) of IKKα/β phosphorylation at Ser176/180, corrected for the corresponding 
total IKKα/β content and normalised using the sham operated band. Each immunoblot is from a single 
experiment. Data are presented as mean ± SEM of n observations, ★P<0.05 vs. sham + vehicle. 
Western blots performed by Massimo Collino & Fausto Chiazza. 
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The Effect of Late Inhibition of IKK on the Phosphorylation of eNOS in the Rat 
Kidney 
Rats subject to 30 min of unilateral renal ischaemia demonstrated a significant 
reduction in the phosphorylation of Ser1177 on eNOS when compared to sham-
vehicle rats (Figure 2.12).  The administration of 1.0 mg/kg IKK16 24 h after the 
onset of reperfusion also successfully attenuated the IRI-dependent decrease in the 
















Figure 2.12 The effect of late administration of 1.0 mg/kg IKK16 (24 h into reperfusion) on ischaemia-
reperfusion injury on the activation of endothelial nitric oxide synthase (eNOS) at 48 h of reperfusion. 
The activation of eNOS was measured as phosphorylation of Ser1177. Sham + vehicle: n=4; IRI + 48 h: 
n=4; IRI + 48 h + IKK16 1.0mg/kg: n=4. IRI; ischaemia-reperfusion injury. Densitometric analysis of 
the bands is expressed as relative optical density (OD) of eNOS phosphorylation at Ser1177, corrected for 
the corresponding total eNOS content and normalised using the sham operated band. Each immunoblot 
is from a single experiment. Data are presented as mean ± SEM of n observations, ★P<0.05 vs. IRI 48 




Effect of Time on Renal Injury post Ischaemia-Reperfusion and the Effect of 
Late Inhibition of IKK on Tubular Dilatation 
 
When compared to baseline (sham animals), rats that underwent 30 min of 
unilateral renal ischaemia developed histological signs of significant renal injury at 
48 h of reperfusion, such as glomerular shrinkage, tubular dilatation, basophilia, 
necrosis and luminal congestion (Figure 2.13).  
 
When compared with sham-operated rat kidneys (Figure 2.13A), kidneys from rats 
that underwent 30 min of unilateral renal ischaemia and 48 h of reperfusion (Figure 
2.13C), and 72 h of reperfusion (Figure 2.13D) exhibited a significant degree of 
renal injury (tubular dilatation), which was significantly reduced by administration 















Figure 2.13 The effect of late administration of IKK16 (24 h into reperfusion) on ischaemia-reperfusion 
injury on histological injury subsequent to 30 min ischaemia and 48 h reperfusion. IRI; ischaemia-
reperfusion injury. Representative histological H&E images of rat renal tissue were taken from sham + 
vehicle (A), after 24 h of reperfusion, IRI + 24 h (B) after 48 h of reperfusion, IRI + vehicle (C), after 
72 h of reperfusion, IRI + 72 h (D) and after 48 h of reperfusion with treatment of IKK16 (1.0 mg/kg 
i.v.) 24 h into reperfusion (E). IRI: ischaemia-reperfusion injury. Ten randomly selected fields from 
three individual kidneys (n=3) per group were selected and analysed (total fields per group = 30) for the 
determination of percentage background white space using ImageJ software and represented as 
percentage tissue surface area per field (F). Data are presented as mean ± SEM of n observations, 







In this chapter, I have characterised the time course of AKI in a rat model of renal 
IRI. Thirty min of ischaemia caused a significant renal (as demonstrated by serum 
urea and SCr), glomerular (as demonstrated by the eCCL) and tubular (as 
demonstrated by the FENa+) dysfunction after 24 h of reperfusion, with subsequent 
reversal towards baseline after this period. AKI is a reversible condition; in this 
chapter I have demonstrated an acute injury phase, with function returning to near 
baseline after 72 h of reperfusion. The AKIN guidelines state that the definition for 
AKI is ‘an abrupt (within 48 h) reduction in kidney function currently defined as an 
absolute increase in SCr of more than or equal to 0.3 mg/dl (≥26.4µmol/l), a 
percentage increase in SCr of more than or equal to 50% (1.5-fold from baseline), 
or a reduction in urine output (documented oliguria of less than 0.5ml kg/h for more 
than 6 h)’ (Mehta et al., 2007). The IRI time course here demonstrates a similar 
increase in SCr at 48 h post reperfusion as described in the AKIN guidelines (sham 
+ vehicle 41.91±1.71 to 198.58±21.63). The urine output was not measured in the 
first 24 h after IRI in these animals due to home office regulations.  
 
In addition to studying the renal function of these animals, I measured the 
activation of IκB and IKK and the NF-κB nucleus to cytosol ratio. NF-κB is 
activated in inflammatory states such as AKI (Sanz et al., 2010) by a wide range of 
stimuli e.g. TLR activation (TLR2 and TLR4 in renal IRI) (Mudaliar et al., 2013), 
TNF-α (Donnahoo et al., 2000) and angiotensin II (Ono et al., 2015). In this 
chapter, I have demonstrated a significant increase in the p65 NF-κB 
nucleus/cytosol ratio (indicating nuclear translocation of p65), the phosphorylation 
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of IKKα/β at Ser176/180 and the phosphorylation of IκBα at Ser32/26 in the renal tissue 
at 48 h post reperfusion. The phosphorylation of IKKα/β at Ser176/180 indicates IKK 
activation, which in turn causes phosphorylation of Ser32/36 on IκBα. IκBα then 
dissociates from NF-κB, resulting in NF-κB translocation to the nucleus and DNA 
transcription of inflammatory genes. Similarly, Patel et al. (2012) have 
demonstrated an increase in the p65 NF-κB nucleus/cytosol ratio at 48 h in a 
bilateral rat model of IRI (Patel et al., 2012). At 72 h post reperfusion, the 
phosphorylation of IKKα/β at Ser176/180, the phosphorylation of IκBα at Ser32/26 and 
the p65 nucleus/cytosol ratio return to sham-like levels, indicating an acute 
inflammatory period.  
 
Furthermore, at 48 h post reperfusion, the phosphorylation of eNOS at Ser1177 was 
significantly reduced when compared to sham animals. The degree of IRI is directly 
proportional to the activity of eNOS: more severe IRI is associated with a lower 
eNOS expression (Shoskes et al., 1997), and the generation of superoxide radicals 
(Noiri et al., 2001). Reduced eNOS expression in this case may be explained by 
eNOS ‘coupling’ and ‘uncoupling’. eNOS is a homodimer consisting of an 
oxygenase and a reductase domain (Raman et al., 1998). Upon activation, eNOS 
dissociates from caveolin-1 (to which it is constitutively bound) (Gratton et al., 
2000). Electron flow is generated by the oxidation of NADPH to NADP+, and the 
electrons continue through flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) in the reductase domain. The cofactor tetrahydrobiopterin 
(BH4) is critical in this reaction, facilitating the interaction between the reductase 
and oxygenase domains (Raman et al., 1998), passing the electron flow from FMN 
in the reductase domain into the haem complex of the oxygenase domain. Here, NO 
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is produced from molecular oxygen, via the oxidation of L-arginine to L-citrulline. 
The role of BH4 in this pathway is described as being ‘coupled’ to eNOS (Schmidt 
and Alp, 2007) (Figure 2.12). In pathological conditions, including ischaemia, the 
level of BH4 is limiting or absent (Channon, 2004). This causes the electron 
transfer from the flavins to L-arginine oxidation to become ‘uncoupled’, producing 
superoxide from molecular oxygen (Schmidt and Alp, 2007) (Figure 2.12). BH4 
therefore is critical for the normal function of eNOS, which when ‘uncoupled’ 
causes oxidative stress to tissues. The activation of eNOS is measured at multiple 
sites, the most studied include Ser1177, the activation site, which is only possible to 
measure when eNOS is coupled, and Thr495, the inhibitory site (Chen et al., 1999).  
Figure 2.12 The mechanism of eNOS A) coupling and B) uncoupling. When eNOS is coupled, 
oxidation of NADPH to NAPD+ generates electron flow, through flavins FAD and FMN in the 
reductase domain of the enzyme. Electron flow to the oxygenase domain is facilitated by 
tetrahydrobiopterin (BH4) where the catalysation of L-arginine is oxidated to L-citrulline occurs 
(A). BH4 is limited or absent when eNOS is ‘uncoupled’, causing electron transfer to from the 
flavins to L-arginine to become uncoupled. eNOS now produces superoxide radicals, causing 
oxidative stress in tissue (B). NADPH, nicotinamide adenine dinucleotide phosphate; NADP, the 
oxidised form of NADPH; FAD, flavin adenine dinucleotide; FMN flavin mononucleotide; BH4, 
tetrahydrobiopterin; Fe, the ferrous- dioxygen complex; O2, molecular oxygen; NO, nitric oxide; 
O2-.superoxide. Adapted from (Channon, 2004). 
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Previous studies have similarly demonstrated a decrease in eNOS expression post 
IRI at both 24 h (Zhang et al., 2014) and 48 h (da Costa et al., 2015) when 
compared to sham-operated animals. I therefore propose that eNOS is uncoupled at 
48 h post reperfusion in this model of renal IRI. 
 
As there are no proven medical therapies to improve short-term prognosis of AKI 
(Heung and Chawla, 2012), i.e. to aid recovery or tissue repair, I have sought to 
identify a novel drug target to attenuate the course of AKI during its development 
(not as a pre-treatment and not on reperfusion, but after initiation of disease). In this 
study, I have identified the development of AKI using SCr and eCCL to be at 24 h 
after the onset of reperfusion (peak dysfunction). Patients with AKI present with 
high SCr, which is usually diagnosed between 24 and 72 h after the insult 
(Bagshaw et al., 2010). Using the time course data generated so far, I decided to 
treat the animals at 24 h post reperfusion as this was i) the peak of renal dysfunction 
measured in these animals, (increases in serum urea, SCr and the FENa+, and a 
decrease in the eCCL) and ii) prior to NF-κB activation (as shown by the p65 
nucleus/cytosol ratio).  
With this information, I selected an IKK inhibitor, IKK16, screened from a 
Novartis compound archive for ‘hits’ with a typical kinase motif and the dose range 
for this study determined based on previously calculated IC50 values (Waelchli et 
al., 2006). Animals were administered 0.1, 0.3 or 1.0 mg/kg IKK16 i.v. at 24 h post 
reperfusion. Lower doses of IKK16 (0.1 and 0.3 mg/kg) had no significant effects 
of any of the biochemical parameters measured, however the administration of 1.0 
mg/kg IKK16 at 24 h after the onset of reperfusion significantly attenuated markers 
of renal and glomerular dysfunction (as measured by SCr, urea and eCCL) and 
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tubular dysfunction (as measured by FENa+). For the purpose of this thesis, the 
dose of 1.0 mg/kg IKK16 was used for all further experiments. 
 
The activation of IκBα and the translocation of the NF-κB p65 subunit from the 
nucleus to the cytosol were abolished following the inhibition of IKK with IKK16 
at 24 h of reperfusion. Further to this, the phosphorylation of IKKα/β was 
attenuated by the administration of IKK16. These results indicate that 1.0 mg/kg 
IKK16 was sufficient to inhibit IKK, preventing IκBα phosphorylation, IKK 
activation and subsequent NF-κB dissociation and translocation to the nucleus for 
the transcription of inflammatory genes. In both clinical and pre-clinical renal IRI, 
NF-κB activation plays a major role in the inflammatory response, regulating the 
cell biology of neutrophils, macrophages, lymphocytes and dendritic cells (Sanz et 
al., 2010). Previous studies have inhibited NF-κB via decoy DNA 
oligodeoxynucleotides, attenuating renal IRI injury, MCP-1, ICAM-1, (and 
therefore monocyte/macrophage infiltration), iNOS and ET-1 expression compared 
to control animals, highlighting the impact NF-κB has on the inflammatory 
response post IRI (Cao et al., 2004). The inhibition of IKKβ with siRNA 48 h prior 
to renal IRI in vivo, caused a significant reduction in macrophage infiltration, NF-
κB DNA binding activity, NGAL and IL-18 expression (Wan et al., 2011a). I 
anticipate that if measured, there would be a similar attenuation in inflammatory 
markers in my model after the inhibition of IKK, due to the successful inhibition of 
IKK, the prevention of NF-κB nuclear translocation and therefore the reduction in 
inflammatory gene transcription. 
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Interestingly, the inhibition of IKK with a single dose of IKK16 administered 24 h 
post reperfusion restored the IRI-dependent decrease in the level of eNOS in the 
kidney tissue. eNOS is upstream of IKK, however, Chen et al. (2002) have 
demonstrated that heat shock protein 90 (hsp90), a molecular chaperone protein 
important in eNOS regulation, binds IKKα and IKKβ at their kinase domains (Chen 
et al., 2002). Hsp90 interacts with eNOS and Akt (involved in cell survival) 
functioning as a ‘scaffold’, facilitating Ser1177 phosphorylation when eNOS is 
activated (Fontana et al., 2002). Mohan et al. (2009) have previously inhibited 
IKKβ expression by wedelolactone (an IKKβ inhibitor) or by siRNA in endothelial 
cells subject to high glucose conditions. The inhibition of IKKβ resulted in an 
increased eNOS-Hsp-90 interaction and a subsequent increase in NO production, 
demonstrating eNOS re-coupling (Mohan et al., 2009). Aside from the high glucose 
conditions, the resultant uncoupling of eNOS and the production of superoxide 
radicals (Lin et al., 2005) mirrors the pathogenesis of IRI. These experiments have 
only been performed in malignant or transformed cell lines however, and have yet 
to be confirmed in vivo. 
 
The restoration of phosphorylated eNOS to sham-like levels in IKK16 treated 
animals is beneficial, as NO production causes local vasodilatation, inhibition of 
platelet aggregation and is involved in the regulation of angiogenesis (Luque 
Contreras et al., 2006). Compounds which restore eNOS coupling and NO 
production are beneficial in the treatment of renal IRI. I speculate that IKK16 
administration inhibits IKK, resulting in an increase in eNOS-Hsp90 interaction. 
An increase in eNOS-Hsp90 interaction causes Ser1177 phosphorylation and the 
consequent ‘re-coupling’ of eNOS (and therefore an increase in the production of 
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NO). The mechanism of this is still unclear as the relationship of IKK and eNOS 
has yet to be described further.  
 
In addition to functional data, kidney sections were stained with H&E to analyse 
structural changes before and after renal IRI. Using Image J software I quantified 
tubular dilatation in each image. In this chapter, I demonstrate a significant increase 
in tubular dilatation at 24, 48 and 72 h post IRI, a hallmark of AKI pathology. The 
inhibition of IKK at 24 h post reperfusion significantly reduced tubular dilatation. It 
was previously thought that the kidney had the ability to recover completely both 
functionally and structurally after acute injury (Sharples, 2007), however this was 
dispelled recently as tubules may exhibit growth arrest, failure to redifferentiate and 
atrophy post AKI, which may aid a prolonged inflammatory state, the production of 
fibrosis and the development of CKD (Venkatachalam et al., 2015). The delayed 
administration of IKK may, therefore, accelerate the rate of structural recovery and 
potentially retard the development of fibrosis. This will be discussed in greater 
detail in the next chapter. 
 
In this chapter, I have studied the time course of AKI, presenting the activation of 
NF-κB over a 72 h reperfusion period following 30 min of IRI. Using this time 
course I decided to treat the animals 24 h post reperfusion at the peak of renal 
dysfunction (maximal SCr) and before the activation of NF-κB. The inhibition of 
IKK successfully attenuated renal dysfunction and structural alterations seen in 
AKI, likely caused by a reduction in the transcription of inflammatory genes 
resulting in a reduction in excessive inflammation. Moreover, I have shown in this 
chapter that renal IRI causes a significant decrease in eNOS phosphorylation at 
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Ser1177 (eNOS ‘uncoupling’) at 48 h post reperfusion, which was restored and 
possibly ‘recoupled’ by the delayed inhibition of IKK at 24 h post reperfusion. The 
most interesting and novel finding presented in this chapter is that renal IRI may be 

















































The Delayed Administration of IKK16 
Reduces Renal Fibrosis After an 
Extended Reperfusion Period in a Rat 






It is now widely recognised that AKI is a major risk factor for CKD even in those 
patients who regain full renal function post AKI (Hsu, 2012). For patients who 
recover from AKI, there is a 25% increase in the risk of CKD, and this is associated 
with a mortality rate of up to 50% after 10 years (Bucaloiu et al., 2012). AKI to 
CKD progression has been demonstrated in both the clinical (Hsu, 2012), and the 
pre-clinical setting (experimental animal models) (Basile et al., 2001) (Clements et 
al., 2013). Progression from AKI to CKD is associated with a series of 
inflammatory changes in the kidney including tubular injury, tubular obstruction, 
vascular injury, endothelial cell activation and leukocyte recruitment (Isaac et al., 
2007) (Arfian et al., 2012). Following AKI, prolonged inflammation, and 
maladaptive or incomplete regenerative processes encourage the development of 
fibrosis and CKD (Lee and Kalluri, 2010), which may or may not result in ESRD. 
 
Common animal models used to study CKD include the 5/6 nephrectomy model 
(5/6 of the kidney mass is removed resulting in a reduction in GFR and the 
development of fibrosis), and the UUO model (ureteral ligation causes back leak of 
urine and increased pressure in the kidney resulting in a widespread 
tubulointerstitial fibrosis, which is not dissimilar to human disease) (Chevalier et 
al., 2009). However, in light of new clinical data describing the progression of AKI 
to CKD following the development of renal fibrosis, a new approach to studying its 
pathophysiology has emerged. Now, extension of the reperfusion period of the 
renal IRI model for a number of weeks gives a more accurate representation of the 
clinical situation. The renal IRI may be bilateral, unilateral, or unilateral with 
contralateral nephrectomy. Previously, the acute phase of AKI was studied in great 
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detail and experiments terminated soon after injury, with the assumption that the 
complete functional recovery is associated with complete structural recovery 
(Sharples, 2007). However, it is now known that even one episode of ischaemia 
may lead to the production of fibrotic tissue (Azuma et al. 1997). Models of AKI 
with an extended reperfusion period have been used to target multiple proteins and 
receptors, such as αKlotho (a cytoprotective protein) (Shi et al., 2015), IL-34 
(upregulated after IRI, worsening subsequent fibrosis) (Baek et al., 2015) and 
antagonism of the mineralcorticoid receptor (Barrera-Chimal et al., 2013), to name 
a few. The role of IKK has not yet been studied in progression of AKI to CKD; 
however, non-specific GSK-3 inhibitors have been studied in a similar model 
(Singh et al., 2015). GSK-3 is a kinase that converges many signalling pathways, 
and has the ability to phosphorylate more than 40 proteins (Jope and Johnson, 
2004). GSK-3 inhibitors inhibit NF-kB, however, as GSK-3 is involved in the Wnt 
pathway and insulin signalling, it is impossible to say with certainty that the effects 
of these inhibitors is through NF-kB inhibition alone (Ansaldi et al., 2011). Singh et 
al. (2015) used a mouse model of bilateral IRI with either pre- (GSK-3 inhibitor 
TDZD 1 hr prior to surgery and once per day thereafter for 12 days) or post  (GSK-
3 inhibitor TDZD 48 h after surgery and once per day thereafter for 12 days) 
ischaemia, concluding that GSK-3 could promote fibrosis of the kidney through the 
activation of TGF-β signalling pathways (Singh et al., 2015). TDZD has previously 
been shown to decrease the activity of NF-kB in a rat model of myocardial IRI 
(Gao et al., 2009).  
I decided to target IKK as it is directly upstream of NF-kB, and may play a role in 
the development of fibrosis. NF-kB has previously been shown to be activated in 
CKD; in rats, adenine diet-induced CKD exhibited a prolonged activation of NF-kB 
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and a significant development of fibrosis when compared to rats given a normal 
chow diet (Vaziri et al., 2014). 
The role of IKK in renal fibrosis has yet to be described. However, early IKK 
inhibition has proven to be an effective therapeutic target in other fibrotic diseases. 
The early inhibition of IKK, i.e. before and during the development of injury, in a 
mouse model of non-alcoholic fatty liver disease successfully attenuated the 
formation of myofibroblasts (Wei et al., 2011). In addition, the constitutive 
activation of IKKβ in cardiomyocytes in an inducible transgenic mouse model 
resulted in heart failure with concomitant collagen deposition (Maier et al., 2012) 
suggesting IKK to be an important inducer of fibrosis following inflammation. 
Furthermore, the inhibition of IKK suppresses airway remodelling in a mouse 
model of chronic asthma, via the attenuation of collagen formation, myofibroblast 
formation and total TGF-β1 production and activation (Ogawa et al., 2011). 
 
In this chapter, I sought out to determine the effect of IKK inhibition on an 
extended reperfusion period following renal IRI, to see whether early reduction in 
renal dysfunction and injury after the delayed administration (at 24 h) of an IKK 
inhibitor, IKK16 (as seen in Chapter II), would prevent subsequent development of 
fibrosis (and consequent CKD). I used Sirius red staining as a marker of collagen 
deposition, and analysed whole cross sections of rat kidneys to study the effect that 




Methods and Materials 
 
Animal experiments were carried out as previously described in Chapter II, 
however the reperfusion period was extended up to 28 days. This study was carried 
out on 45 male Wistar rats. Three animals were excluded from the study due to 
early mortality, a likely consequence of insufficient reperfusion of the kidney 
following renal IRI. Mortality occurred in the first three days post-IRI. Surviving 
animals gained significant weight and displayed no signs of illness from days 4-28.  
 
Experimental Design  
Renal Ischaemia-Reperfusion injury, with extended reperfusion period 
Rats were randomly allocated into the following groups: (i) Sham + vehicle: n=8 
(i) 1 day post reperfusion: n=4; (iii) 2 days post reperfusion: n=4; (iv) 7 days 
post reperfusion: n=4; (v) 14 days post reperfusion: n=4; (vi) 28 days post 
reperfusion: n=7; (vii) 1.0 mg/kg IKK16 24 h post reperfusion + 7 day 
reperfusion: n=7; (viii) 1.0 mg/kg IKK16 24 h post reperfusion + 28 day 
reperfusion: n=7. Rats were administered vehicle (10% DMSO) or IKK16 24 h 
after the onset of reperfusion via the tail vein at a volume of 1 ml/kg. IKK16 was 
purchased from Tocris Bioscience (R&D systems Europe, Abingdon, UK), and 
used at the previous efficacious dose of 1.0 mg/kg as determined in chapter II. 
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Measurement of biochemical parameters 
All biochemical markers in serum and urine were measured in a blinded fashion by 
a commercial veterinary testing laboratory (IDEXX Ltd, West Sussex, UK). 
Parameters measured were described as in Chapter II.  
Picrosirius Red Staining 
Sections were deparraffinized and rehydrated through graded alcohols to distilled 
water. Sections were treated with phosphomolybdic acid (Polysciences, 
Warrington, PA), rinsed in distilled water and stained with picrosirius red 
(Polysciences, Warrington, PA) for 60 min at room temperature.  Sections were 
then immediately immersed in hydrochloric acid for 2 min (Polysciences, 
Warrington, PA) before being dehydrated through graded alcohols and cleared. 
Images of whole cross sections were taken with a Nanozoomer Digital Pathology 
Scanner (Hamamatsu Photonics K.K., Japan), and quantification of Sirius red 




Sections cut at 4 µm were de-waxed, and deparaffinized to phosphate-buffered 
saline (PBS). Antigen retrieval was performed by microwaving (700W) sections in 
citrate buffer (pH 6.0) for 15 min. Once cooled, sections were incubated with 
0.03% H2O2 for 20 min to inactivate endogenous peroxidases (Dako EnVision+ 
System-HRP-DAB, K4010), and subsequently treated with 10% normal goat serum 
(Dako, UK) to reduce non-specific absorption. Sections were subsequently 
incubated at 37oC for 1 h with the following primary antibodies: anti-α-SMA 
antibody (1:400, cat#ab5694, Abcam, UK) or anti-CD68 antibody ED1 (1:400; 
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cat#MCA341R, AbD Serotec, UK), washed with PBS and then incubated at room 
temperature for 30 min with labelled polymer-HRP antibody (Dako EnVision+ 
System-HRP-DAB). Sections were developed in DAB chromagen solution, and the 
reaction stopped by immersion of sections in water. Counterstaining was performed 
with Harris haematoxylin before sections were dehydrated and mounted in DPX 
mounting medium. Images of whole sections (for α-SMA analysis) and ten images 
per section (for CD68+ analysis) were acquired with a Nanozoomer Digital 
Pathology Scanner (Hamamatsu Photonics K.K., Japan), in a double-blinded 




Western blots were performed in the same fashion as described in chapter II. 
Membranes were incubated with primary antibody; rabbit anti-TGF-β (1:1000, 
cat#ab66043); rabbit anti-fibronectin (1:1000, cat#ab2413, Abcam, UK); rabbit 
anti-pSmad2 Ser465/467/Smad3 Ser423/425 (1:1000, cat#D27F4, Cell Signalling 
Technologies, MA); rabbit anti-Smad2/3 (1:1000, cat#D7G7, Cell Signalling 
Technologies, MA); rabbit anti-vimentin (1:1000, cat#D21H3, Cell Signalling 
Technologies, MA). The blots were then incubated with the appropriate secondary 
antibody conjugated with horseradish peroxidase (dilution 1:10000) and developed 
using the ECL detection system. The immunoreactive bands were visualized by 
autoradiography. The membranes were stripped and incubated with rabbit 
glyceraldehyde-3-phosphate dehydrogenase (GADPH) antibody (1:1000, 
cat#D16H11, Cell Signalling Technologies, MA) instead of β-actin due to the 
involvement of β-actin the in cytoskeleton. 
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Materials 
Unless otherwise stated, all compounds used in this study were purchased from 
Sigma-Aldrich Company Ltd. (Poole, Dorset, U.K.).  
 
Statistical Analysis 
All values described in the text and figures are expressed as mean±SEM for n 
observations. Each data point represents biochemical measurements obtained from 
up to 11 separate animals. Statistical analysis was carried out using GraphPad 
Prism 6.0b (GraphPad Software, San Diego, California, USA). Data without 
repeated measurements was assessed by one-way ANOVA followed by 
Bonferroni’s multiple-comparison post hoc test. Linear regressions were calculated 
by the least squares method and their significance were estimated by a Fisher F test. 















The Effect of 28 days Reperfusion on Renal Functional Biomarkers Following 
Renal Ischaemia-Reperfusion Injury 
 
After an extended reperfusion period of 28 days, animals subject to 30 min of 
unilateral renal ischaemia and administered either vehicle or IKK16 24 h post 
reperfusion demonstrated no significant differences in serum urea or SCr when 









Figure 3.1 The effect of an extended reperfusion period (28 days) after 30 min renal ischaemia on 
markers of renal function. (A) Serum urea and (B) serum creatinine were measured as indicators of 
renal function. Sham + vehicle: n=4; IRI + vehicle: n=8; IRI + IKK16 1.0 mg/kg: n=7. Data are 
presented as mean ± SEM of n observations. 
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The Effect of 28 days Reperfusion on Kidney Weight Following Renal 
Ischaemia-Reperfusion Injury 
 
Compared to sham animals, animals subject to 30 min of ischaemia and 28 days of 
reperfusion administered either vehicle control or IKK16 24 h post reperfusion 
demonstrate significant increases in the kidney weight as % of body weight. There 
was no significant difference between vehicle control or IKK16 treated groups 






Figure 3.2 The effect of an extended reperfusion period (28 days) after 30 min renal ischaemia on 
kidney weight as a percentage of total body weight. Sham + vehicle: n=4; IRI + vehicle: n=8; IRI + 
IKK16 1.0 mg/kg: n=7. Data are presented as mean ± SEM of n observations. ★P<0.05 vs. IRI + 
vehicle.  
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Effect of Late Inhibition of IKK on Sirius Red staining in the Rat Kidney after 28 
days Reperfusion 
 
Despite no change in renal functional parameters after renal IRI at 28 days post IRI 
(Figure 3.2), when compared with sham-operated rats, kidneys from rats that 
underwent 30 min of unilateral renal ischaemia and 28 days of reperfusion 
exhibited a significant increase in Sirius red staining, indicating the development of 
fibrosis (Figure 3.3). Administration of IKK16 (1.0 mg/kg) 24 h after the onset of 
reperfusion significantly attenuated the increase in Sirius red staining for collagen I 
and III, and therefore fibrosis, when compared to vehicle treated animals (Figure 
3.3).  
Representative cross sections of the kidneys from the time course, stained for Sirius 
red are displayed in Figure 3.4, and representative images at x20 magnification in 












Figure 3.3 The time course of development of fibrosis (as measured by Sirius red for Collagen I and 
III) after unilateral renal ischaemia (30 min) and reperfusion (up to 28 days), and the effect of the late 
administration of IKK16 at 24 h post reperfusion. Sham + vehicle: n=4; 1 day post reperfusion: n=4; 2 
days post reperfusion: n=4; 7 days post reperfusion: n=4; 14 days post reperfusion: n=4; 28 days post 
reperfusion: n=8; 1.0 mg/kg IKK16 24 h post reperfusion + 28 day reperfusion: n=7. Due to the 
concentration of the fibrosis in the corticomedullary junction, whole tissue cross sections (as seen in 
Figure 3.4) were analysed and the % staining for Sirius red per tissue field calculated by ImageJ 
software. Data are presented as mean ± SEM of n observations, ★P<0.05 vs. sham + vehicle, unless 











































































































































































































































































































































































































Figure 3.5 The time course of development of fibrosis (as measured by Sirius red for Collagen I and 
III) after unilateral renal ischaemia (30 min) and reperfusion (up to 28 days), and the effect of the late 
administration of IKK16 (24 h post reperfusion.  Images depict representative images of Sirius red 
stained kidneys at x20 magnification, quantitative data can be found in Figure 3.3.  (A) Sham + 
vehicle (B) 1 day post reperfusion (C) 2 days post reperfusion (D) 7 days post reperfusion (E) 14 days 
post reperfusion (F) 28 days post reperfusion (G) 1.0 mg/kg IKK16 24 h post reperfusion + 28 days 
reperfusion.  
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Interestingly, regression analysis revealed a significant linear relationship between 
SCr time course evolution (AUC) and Sirius red staining (Figure 3.5C). More 
specifically, Sirius red staining after 28 days was significantly related to SCr levels 
or eCCL at day 2 (Figure 3.5A, 3.5B).  
 
 
Figure 3.6 Correlation data to show (A) serum creatinine at day 2 vs. Sirius red percentage per tissue field 
(indicative of fibrosis) at day 28 (B) the estimated creatinine clearance at day 2 v.s. Sirius red percentage per 
tissue field at day 28 and (C) the area under the curve (AUC) (from day 0 to day 28) vs. Sirius red 
percentage per tissue field at day 28. All animal data generated in this study (sham + vehicle, IRl + vehicle 
and IRI + 1.0 mg/kg IKK16 24 h post reperfusion) is included in these graphs. Linear regressions were 
calculated by the least squares method and their significance were estimated by a Fisher F test. P<0.05 was 
considered to be significant.	
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Effect of Late Inhibition of IKK on Myofibroblast Activation in the Rat Kidney 
after 28 days Reperfusion 
 
I then stained sections from the entire time course for α-SMA to determine 
myofibroblast activation. When compared with sham-operated rats, kidneys from 
rats that underwent 30 min of unilateral renal ischaemia and 7 days of reperfusion 
exhibited a significant increase in α-SMA staining, and therefore myofibroblast 
activation (Figure 3.7). Administration of IKK16 (1.0 mg/kg) 24 h after the onset of 
reperfusion significantly attenuated the increase in α-SMA staining at 7 days post 
reperfusion (Figure 3.7). Interestingly, vehicle treated rats culled at 7 days post 
reperfusion were the only group in the entire time course (from sham to 28 days), 
displaying significant increases in myofibroblast formation when compared to 
sham-operated rats. Representative cross sections of kidneys from the time course 
stained for α-SMA are displayed in Figure 3.8, and representative images at x20 



















Figure 3.7 The effect of the late administration of IKK16 (24 h post reperfusion) on α-SMA staining for 
α-SMA-positive myofibroblasts after unilateral renal ischaemia (30 min) and reperfusion (up to 28 days). 
Sham + vehicle: n=8, 1 day post reperfusion: n=4; 2 days post reperfusion: n=4; 7 days post reperfusion: 
n=4; 14 days post reperfusion: n=4; 28 days post reperfusion: n=7; 1.0 mg/kg IKK16 24 h post 
reperfusion + 7 day reperfusion: n=7; 1.0 mg/kg IKK16 24 h post reperfusion + 28 day reperfusion: n=7. 
Due to the concentration of α-SMA in the corticomedullary junction, whole tissue cross sections (as seen 
in Figure 3.8) were analysed and the % staining for α-SMA per tissue field calculated by ImageJ software. 










































































































































































































































































































































































































































Figure 3.9   The effect of the late administration of IKK16 (24 h post reperfusion) on α-SMA staining 
for α-SMA-positive myofibroblasts after unilateral renal ischaemia (30 min) and reperfusion (up to 28 
days). Images depict representative images of α-SMA stained kidneys at x20 magnification. Quantative 
data can be found in Figure 3.7. (A) Sham + vehicle (B) 1 day post reperfusion (C) 2 days post 
reperfusion (D) 7 days post reperfusion (E) 14 days post reperfusion (F) 28 days post reperfusion (G) 
1.0 mg/kg IKK16 24 h post reperfusion + 7 days reperfusion (H) 1.0 mg/kg IKK16 24 h post 
reperfusion + 28 days reperfusion. 
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Effect of Late Inhibition of IKK on CD68+ staining in the Rat Kidney after 28 
days Reperfusion 
 
It is known that macrophages are a major producer of TGF-β in fibrosis (Kim et al., 
2015). Thus, I stained the entire time course for CD68+, a glycoprotein found in 
cytoplasmic granules of cells of the macrophage lineage. When compared with 
sham-operated rats, kidneys from rats that underwent 30 min of unilateral renal 
ischaemia and 7 days of reperfusion exhibited a significant increase in CD68+ 
staining, and therefore macrophage infiltration (Figure 3.10). Administration of 
IKK16 (1.0 mg/kg) 24 h after the onset of reperfusion significantly attenuated the 
increase in CD68+ staining at 7 days post reperfusion (Figure 3.10). Interestingly, 
vehicle treated rats culled at 7 days post reperfusion were the only group in the time 
course (from sham to 28 days), which displayed significant increases CD68+ when 
compared to sham-operated rats. Representative images at x40 magnification are 

















Figure 3.10 The effect of the late administration of IKK16 (24 h post reperfusion) on CD68+ staining, 
indicative of macrophages, after unilateral renal ischaemia (30 min) and reperfusion (up to 28 days). 
Ten randomly selected fields (at x40 magnification) from each kidney were selected and analysed for 
the determination of percentage stained rat kidney tissue using ImageJ software. Sham + vehicle: n=8 
(80 total fields), 1 day post reperfusion: n=4 (40 total fields); 2 days post reperfusion: n=4 (40 total 
fields); 7 days post reperfusion: n=6 (60 total fields); 14 days post reperfusion: n=4 (40 total fields); 28 
days post reperfusion: n=7 (70 total fields); 1.0 mg/kg IKK16 24 h post reperfusion + 7 day reperfusion: 
n=7 (70 total fields); 1.0 mg/kg IKK16 24 h post reperfusion + 28 day reperfusion: n=7 (70 total fields). 




Figure 3.11 The effect of the late administration of IKK16 (24 h post reperfusion) on CD68+ staining, 
indicative of macrophages, after unilateral renal ischaemia (30 min) and reperfusion (up to 28 days). 
Images depict representative images of CD68+ stained kidneys at x40 magnification. Quantative data can 
be found in Figure 3.10. (A) Sham + vehicle (B) 1 day post reperfusion (C) 2 days post reperfusion (D) 7 
days post reperfusion (E) 14 days post reperfusion (F) 28 days post reperfusion (G) 1.0 mg/kg IKK16 24 h 




Effect of Late Inhibition of IKK on Pro-fibrotic markers in the Rat Kidney at 7 
days Post Reperfusion 
 
When compared with sham-operated rats, kidneys from rats that underwent 30 min 
of unilateral renal ischaemia and 7 days of reperfusion exhibited a significant 
increase in TGF-β (Figure 3.12), and Smad2/3 phosphorylation (Figure 3.13). TGF-
β causes downstream Smad2/3 phosphorylation after type I/II TGF-β receptor 
binding. Administration of IKK16 (1.0 mg/kg) 24 h after the onset of reperfusion 
significantly attenuated the increase in TGF-β (Figure 3.12) and the 













Figure 3.12 The effect of the late administration of IKK16 (24 h post reperfusion) on the expression 
of TGF-β at 7 days post reperfusion. Sham 7 days + Vehicle: n=4; IRI + 7 days Vehicle: n=5: IRI + 7 
days, IKK16 1.0 mg/kg: n=5. Densitometric analysis of the bands is expressed as relative optical 
density (OD) of TGF-β, normalised using the sham operated band. Each immunoblot is from a single 












Figure 3.13 The effect of the late administration of IKK16 (24 h post reperfusion) on the 
expression of both phosphorylated and total Smad2/3 at 7 days post reperfusion. Sham + 7 days, 
Vehicle: n=4; IRI + 7 days, Vehicle: n=5: IRI + 7 days, IKK16 1.0 mg/kg: n=5. Densitometric 
analysis of the bands is expressed as relative optical density (OD) of phosphorylated Smad 2/3, 
corrected for the corresponding total Smad 2/3 content and normalised using the sham operated 
band. Each immunoblot is from a single experiment. Data are presented as mean ± SEM of n 
observations, #P<0.05 vs. Sham, ★P<0.05.  
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Effect of Late Inhibition of IKK on Pro-Fibrotic Markers in the Rat Kidney at 28 
days Post Reperfusion 
 
When compared with sham-operated rats, kidneys from rats that underwent 30 min 
of unilateral renal ischaemia and 28 days of reperfusion exhibited a significant 
increase in TGF-β (Figure 3.14). Administration of IKK16 (1.0 mg/kg) 24 h after 
the onset of reperfusion significantly attenuated the increase in TGF-β when 














Figure 3.14 The effect of the late administration of IKK16 (24 h post reperfusion) on the expression 
of TGF-β. Sham 28 days + Vehicle: n=4; IRI + 28 days Vehicle: n=5: IRI + 28 days, IKK16 1.0 
mg/kg: n=5. Densitometric analysis of the bands is expressed as relative optical density (OD) of 
TGF-β, normalised using the sham operated band. Each immunoblot is from a single experiment. 
Data are presented as mean ± SEM of n observations, ★P<0.05 vs. IRI + vehicle.  
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Effect of Late Inhibition of IKK on Extracellular Matrix Proteins in the Rat 
Kidney at 28 days post reperfusion 
 
When compared with sham-operated rats, kidneys from rats that underwent 30 min 
of unilateral renal ischaemia and 28 days of reperfusion exhibited an increase in 
vimentin (expressed by myofibroblasts) (Figure 3.15). Administration of IKK16 
(1.0 mg/kg) 24 h after the onset of reperfusion significantly attenuated the increase 















Figure 3.15 The effect of the late administration of IKK16 (24 h post reperfusion) on the 
expression of vimentin at 28 days post reperfusion. Vimentin expressed late after injury as an 
indicator of defective repair and abnormal epithelium, and is also a marker of myofibroblast 
formation. Sham 28 days + Vehicle: n=4; IRI + 28 days Vehicle: n=5: IRI + 28 days, IKK16 1.0 
mg/kg: n=5. Densitometric analysis of the bands is expressed as relative optical density (OD) of 
total vimentin, normalised using the sham operated band. Each immunoblot is from a single 
experiment. Data are presented as mean ± SEM of n observations, ★P<0.05 vs. IRI + vehicle.  
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When compared with sham-operated rats, kidneys from rats that underwent 30 min 
of unilateral renal ischaemia and 28 days of reperfusion exhibited an increase in 
fibronectin (an extracellular matrix component) (Figure 3.16). Administration of 
IKK16 (1.0 mg/kg) 24 h after the onset of reperfusion significantly attenuated the 
increase in fibronectin (Figure 3.16) caused by unilateral IRI after a 28-day 
















Figure 3.16 The effect of the late administration of IKK16 (24 h post reperfusion) on the 
expression of fibronectin at 28 days post reperfusion. Fibronectin is a component of the 
extracellular matrix, and is over produced in fibrotic states. Sham + 28 days, Vehicle: n=4; IRI + 28 
days, Vehicle: n=5: IRI + 28 days, IKK16 1.0 mg/kg: n=5. Densitometric analysis of the bands is 
expressed as relative optical density (OD) of total fibronectin, normalised using the sham operated 
band. Each immunoblot is from a single experiment. Data are presented as mean ± SEM of n 






Epidemiological and outcome analysis studies have recently discovered the role of 
AKI in the progression to CKD to ESRD, with tubulointerstitial fibrosis being the 
predominant pathology promoting progression to CKD (Venkatachalam et al., 
2010). The more severe and prolonged the initial ischaemic insult, the higher the 
probability of developing CKD later in life (Chawla et al., 2011). Therefore, the 
quick amelioration of the IRI-dependent changes in biochemical markers following 
AKI by new therapies may reduce the probability of developing CKD. The timing 
of therapy initiation in patients with AKI is currently under debate, with the 
consensus being to deliver early RRTs to these patients to maintain fluid balance 
and solute clearance until recovery of renal function (Shiao et al., 2009). However, 
in practice RRTs are started after complete renal shutdown (Macedo and Mehta, 
2010). As there are no proven medical therapies to improve short-term prognosis of 
AKI (Heung and Chawla, 2012), i.e. to aid recovery or tissue-repair, I have sought 
to identify a novel drug target to attenuate the course of AKI during its 
development (not as a pretreatment and not on reperfusion, but after initiation of 
disease). Therefore, the diagnosis of AKI with eGFR or novel biomarkers (e.g. 
NGAL) plays an important role for the determination of when to start treatment. 
By extending the reperfusion period to 28 days, I have shown that animals subject 
to only 30 min of renal ischaemia develop fibrosis. This is not a model of CKD: the 
animals culled between 7 and 28 days post reperfusion have a renal function 
comparable to sham treated animals. However, this may represent the start of the 
fibrotic process, detrimental to kidney function, which may ultimately lead to CKD 
and even ESRD.  
	 115 
Previous pre-clinical studies have similarly demonstrated an increase in renal 
tubulointerstitial fibrosis at 28 days post renal IRI, described as: ‘mild (fibrosis), 
but there remain significant increases in parameters of fibrosis after IRI’ (Gobe et 
al., 2014), similar to that I have shown in this chapter. Here, I have demonstrated 
that the inhibition of IKK, at 24 h post reperfusion, reduces Sirius red staining for 
collagen I and III and therefore fibrosis, following a 28-day reperfusion period.  
The fibrosis measured was mild, but significantly elevated in vehicle treated 
animals, however, severe enough to demonstrate a reduction in fibrosis after the 
inhibition of IKK.  
I found a significant increase in the kidney weight of both vehicle control and 
IKK16 treated animals, when compared to sham animals. Similar studies 
demonstrate increased kidney weight in relation to total body weight after male 
Wistar rats are subject to IRI for 45 min/42 days (Gonçalves et al., 2014). An 
increase in the kidney weight in animals subject to IRI was explained by Gonçalves 
et al. (2014) as an increase in the fractional interstitial area (Gonçalves et al., 2014). 
There was no significant difference between vehicle treated and IKK16 treated 
groups.  
 
I have also shown a significant correlation between both SCr and the eCCL on day 
2 post IRI vs. fibrosis score at 28 days. Previous clinical studies have demonstrated 
that AKI is a major risk factor for CKD, highlighting the relationship between 
elevated SCr and the risk of CKD development (Coca et al., 2012). SCr is still the 
major clinical biomarker for AKI diagnosis, and its magnitude after events such as 
cardiac surgery has been associated with increased risk of CKD development, 
progression and ESRD (Ishani et al., 2011). This is, however, in reality, more 
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complicated; a recent clinical meta-analysis performed by Coca et al. (2015) 
studied the relationship between acute rises in SCr levels and CKD incidence and 
mortality months later (Coca et al., 2015). This study found no correlation between 
acute rises in SCr and outcome. Underlying clinical conditions (e.g. heart failure), 
age, any interventions given, and curt follow-up periods make translatability of this 
pre-clinical correlation to a meaningful clinical correlation difficult.  However, the 
meta-analysis by Coca et al. (2015) did not measure SCr values of patients over a 
longer period of time (Coca et al., 2015) – something I have done in this study. 
Using these data, I found that the AUC of SCr over the 28 day period following 
renal IRI predicted the severity of fibrosis; which may be a more reliable prediction 
of outcome due to the measurement of SCr over a longer period post AKI. Longer 
follow-up studies with regular measurement of SCr should be executed to 
investigate whether the AUC of SCr is predictive of outcome (fibrosis/CKD) in the 
clinical setting.  
 
In this chapter, I have demonstrated that even when SCr values are ‘normal’ at day 
28, there is a significant development of fibrosis when compared to sham-operated 
animals, and that the development of fibrosis is very much underway before any 
sign of renal functional decline. Barrera-Chimal et al. (2012) used a similar rat 
model of IRI, (bilateral ischaemia, 45 min) with a reperfusion period of 270 days 
(Barrera-Chimal et al., 2013). During the reperfusion period the animals developed 
a progressive renal dysfunction characterized by a reduction in eCCL, a reduction 
in renal blood flow and an increase in proteinuria when compared to sham-operated 
rats (Barrera-Chimal et al., 2013). I speculate there would be a similar decline in 
renal function in vehicle-treated control rats in my model if the reperfusion period 
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was extended to 270 days, furthermore, it would be useful to study whether the 
early amelioration of IRI by the inhibition of IKK would still have benefit (i.e. 
reduced fibrosis/improved renal function) at this time point.   
 
Interestingly, at 7 days post reperfusion after 30 min of renal IRI, there is a 
significant increase in immunohistochemical staining for both α-SMA and CD68+, 
markers for myofibroblast formation and macrophages, respectively. This is prior to 
the development of the formation of fibrosis, and is most likely involved in the 
production of fibrosis seen at 28 days. Both of these parameters returned to near 
baseline at 14 days. Similar data by Ysebaert et al. (2000) have shown an increase 
in macrophage accumulation after renal IRI from 24 h, which is most prominent at 
5 days post reperfusion, and a complete abolishment of macrophages in the renal 
tissue at day 10 (Ysebaert et al., 2000). Macrophages have recently been classified 
into two subsets, M1 (F4/80+ and CD301-, and M2 (F4/80+ and CD301+); after 
renal IRI iNOS-positive pro-inflammatory M1 macrophages polarize to arginase-1 
and mannose receptor positive non-inflammatory macrophages (M2) (Lee et al., 
2011). This switch of phenotype has been described to accompany the change from 
tubular injury to tubular repair (Lee et al., 2011). The phenotype of macrophages 
has also been studied in the development of fibrosis following renal IRI, with M2 
macrophages most abundantly present at 7 days post reperfusion (Lee et al., 2011). 
M2 macrophages are useful in tissue repair (Wang et al., 2007), however they are 
most likely pro-fibrotic in the AKI to CKD progression, synthesizing TGF-β, 
causing downstream signalling through Smad proteins 2/3 regulating transcription 
of genes coding for collagens. There is still much debate whether M2 macrophages 
are beneficial in tissue repair or detrimental because of their role in the 
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development of fibrosis (Braga et al., 2015), however, Myung-Gyu Kim et al. 
(2015) have demonstrated that M2 macrophages were the most predominant 
phenotype 7 – 14 days post unilateral IRI but returned to sham-levels at 28 days 
post unilateral IRI in a mouse model (Kim et al., 2015). Similarly, both studies 
show a peak of macrophage infiltration at 7 days and a reduction in macrophages to 
baseline levels at 28 days. Furthermore, the depletion of macrophages by liposome 
clodronate attenuated IRI-dependent increases in type IV collagen and levels of 
TGF-β, and the re-introduction of M2 macrophages caused an increase in TGF-β 
expression by 2.5 fold when compared to M1 macrophage re-introduction (Kim et 
al., 2015). Similarly, Gharib et al. (2014) found that reduced M2 polarisation 
conferred protection from bleomycin-induced pulmonary fibrosis in a mouse model 
(Gharib et al., 2014). It has previously been demonstrated that macrophage numbers 
closely correlate with glomerular scarring and interstitial fibrosis, demonstrated in 
the biopsy samples of 215 CKD patients (Eardley et al., 2006). I speculate that the 
macrophages at 7 days post reperfusion (reported in this chapter) are M2 
macrophages, that may well be in part responsible for both the increase in TGF-β 
seen at 7 days post reperfusion and the increase in fibrosis at 28 days in vehicle 
treated groups. The inhibition of IKK caused a significant reduction in CD68+ 
staining, and therefore macrophages, at 7 days post reperfusion. Izmailova et al. 
(2006) have previously demonstrated that the inhibition of IKKβ in a murine model 
of arthritis caused a significant reduction in CD68+ macrophages (Izmailova et al., 
2007). The inhibition of NF-κB in bone-marrow derived macrophages via a 
recombinant adenovirus (Ad-IκB) causes a re-orientation of macrophages to an 
anti-inflammatory state, causing a reduction in glomerular inflammation in vivo 
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(Wilson et al., 2005). The exact mechanism of the reduction in macrophages post 
IKK inhibition should be further investigated, as this is still not well understood.  
 
In this rat model of renal IRI I have demonstrated increases in both TGF-β and the 
phosphorylation of Smad2/3 at 7 days post reperfusion. TGF-β directly induces 
fibrosis through Smad3, binding directly to promoter regions to trigger collagen 
production (Meng et al., 2015). TGF-β also induces fibronectin production (Mack 
and Yanagita, 2015), which is significantly increased in this study at 28 days post 
reperfusion in vehicle-treated animals. Furthermore, TGF-β itself promotes the 
transition of various cell types to the myofibroblast phenotype via pericyte-
myofibroblast transition (Wu et al., 2013), EndoMT (Piera-Velazquez et al., 2011), 
EMT (Lan, 2003) and activation of bone-marrow derived sources (LeBleu et al., 
2013), and can directly activate resident renal cells, promoting α-SMA expression 
and fibrosis (Barnes and Glass, 2011). α-SMA is expressed by myofibroblasts, 
major players in the production and deposition of collagen, seen increased here at 7 
days in vehicle treated animals. The inhibition of IKK not only reduced both the 
expression of α-SMA and the infiltration of CD68+ macrophages, but also reduced 
TGF-β and the phosphorylation of Smad2/3. The p65 subunit of NF-κB has 
previously been associated with fibrosis in lung fibroblasts (Sun et al., 2015), and 
the inhibition of IKKβ significantly reduced pulmonary fibrosis in a bleomycin 
mouse model (Inayama et al., 2006). Mia and Bank (2015) have demonstrated that 
IKK inhibition attenuates myofibroblast formation and collagen I production 
induced by TGF-β1, in dermal fibroblasts in vitro (Mia and Bank, 2015), which 




Proximal tubule cells do not constitutively express vimentin, however, AKI causes 
de-differentiation and proliferation of surviving proximal tubule cells, causing an 
increase in vimentin expression later after the insult (Polichnowski et al., 2014). 
Vimentin expressed late after injury is indicative of defective repair and abnormal 
epithelium (Gröne et al., 1987). Vimentin does not only play a role in mechanical 
stabilisation: it is also expressed in cells of mesenchymal origin and therefore is 
commonly used as a marker of EMT (Dave and Bayless, 2014). Renal IRI causes a 
significant increase in vimentin expression in the kidney in vehicle treated animals 
when compared to sham animals, shown here in this chapter. The inhibition of IKK 
at just 24 h post reperfusion caused a significant reduction in vimentin expression at 
28 days. From previous evidence, this suggests that IKK inhibition in this rat model 
of renal IRI with the development of fibrosis, causes a reduction in EMT and a 
reduction in defective repair and abnormal epithelium (Gröne et al., 1987) (Dave 
and Bayless, 2014). 
 
In this study, I have characterized a rat model of unilateral IRI and contralateral 
nephrectomy, with a subsequent development of fibrosis. I have demonstrated that 
the episode of AKI was acute and all functional parameters measured had resolved 
by day 7 onwards. However, during this period, despite the renal function of all 
groups being comparable to sham animals, there was a significant activation of 
macrophages and myofibroblasts, key players the in production of fibrotic tissue 
and the development of fibrosis. The fibrosis measured at 28 days may allude to the 
beginnings of CKD that these animals could develop had the reperfusion period 
been extended. The administration of IKK16, an IKK inhibitor, as a single bolus at 
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24 h post reperfusion significantly attenuated macrophages in the kidney and 
myofibroblast activation at 7 days post reperfusion, which in turn, most likely 
prevented the increase in collagen I and III and therefore fibrosis seen at 28 days in 
the IKK16 treated animals. Further to this, SCr measured at day 2 after IRI was 
predictive of fibrotic score at day 28, and the AUC of SCr measured from day 0 to 
28 was also predictive of fibrotic score at day 28. The early amelioration of IRI is 




















The Delayed Administration of IKK16 
Reduces Renal Fibrosis in a Rat Model 




Currently, the most commonly used in vivo model for renal interstitial fibrosis is 
UUO. When compared to other animal models of renal fibrosis, UUO is a relatively 
short, cheap and easily reproducible model, mimicking many features of CKD seen 
in humans (Eddy et al., 2012). These include: (i) release of proinflammatory 
cytokines and chemokines causing inflammatory mononuclear cell infiltration and 
inflammation, (ii) the production of profibrotic molecules, such as TGF-β (Boor et 
al., 2010) (iii) fibroblast to myofibroblast transition and the consequent expression 
of α-SMA, vimentin and nestin (Grande and López-Novoa, 2009) (iv) EMT 
(another source of myofibroblast generation) (Kalluri and Neilson, 2003) (v) 
increased production of ECM components by myofibroblasts (vi) and expansion of 
the interstitial space due to continuous over production of ECM components 
resulting in tubular hypoxia leading to apoptosis and necrosis of tubular cells 
(Cachat et al., 2003). This pathology is achieved via obstruction of the ureter by 
permanent ligation, causing back leak of urine into the kidney. The resulting 
hydrostatic pressure destroys the kidney architecture, causing apoptosis and 
necrosis of tubular cells (Dendooven et al., 2011). This triggers an inflammatory 
response followed by the development of fibrosis.  
 
As previously discussed in Chapter III, inhibition of NF-κB in animal models of 
fibrosis has proven to be beneficial. Previous studies have demonstrated an increase 
in NF-κB expression up to 7 days post UUO (Kuwabara et al., 2006), and the 
inhibition of NF-κB with curcumin (200 mg/kg/day or 800 mg/kg/day p.o. 7 days 
before UUO and daily thereafter) or the NF-κB inhibitor pyrrolidine 
dithiocarbamate (PDTC) (200 mg/kg/day p.o 1 h before surgery and daily 
thereafter) inhibited NF-κB activation, interstitial macrophage infiltration and 
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fibrosis at 7 days post UUO (Kuwabara et al., 2006). Curcumin from the spice 
turmeric, is known to inhibit NF-κB activation (Singh and Aggarwal, 1995), but 
has also been shown to inhibit c-Jun N-terminal kinase-c-Jun/AP-1 (Chen and Tan, 
1998) and block TGF-β signalling in rat renal fibroblasts (Gaedeke et al., 2004). 
Previous studies have highlighted the role of TGF-β in renal fibrosis: anti-TGF-β 
antibodies prevent renal tubular fibrosis and apoptosis in NRK-52E cells (Miyajima 
et al., 2000) and targeted disruption of Smad3 (directly downstream of TGF-β) 
causes a significant reduction in renal fibrosis, monocyte influx and EMT post 
UUO (Sato et al., 2003). Therefore, the amelioration of fibrosis by curcumin, may 
be partly achieved via inhibition of TGF-β signalling, rather than NF-κB inhibition 
alone. 
A similar study by Tashiro et al. (2003) used PSI, a proteosome inhibitor, blocking 
NF-κB translocation through stabilization of the endogenous NF-κB inhibitor, IκB 
(Tashiro et al., 2003). The administration of 3 mg/kg PSI b.i.d. s.c. attenuated 
UUO-dependent increases in NF-κB DNA binding activity and UUO-dependent 
increases in cortical IκB expression, and a reduction in fibrosis (Tashiro et al., 
2003). EPO, administered q.a.d., has also proven to be successful in reducing 
fibrosis after 14 days of UUO, via the reduction of NF-κB expression (Acikgoz et 
al., 2014). Despite these studies showing the inhibition of NF-κB to be beneficial in 
obstructive nephropathy, the role of IKK, (which is directly upstream of NF-κB) or 
indeed its inhibition, has yet to be studied. In this chapter, I have studied the 
inhibition of IKK in a rat model of UUO, focusing on some of the main hallmarks 
of fibrosis (collagen, myofibroblast formation, TGF-β, fibronectin), to understand 
whether IKK plays a role in the development of fibrosis.  
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Methods and Materials  
 
Animals received standard food and water ad libitum and all protocols followed in 
this study were approved by the local Animal Use and Care Committee in 
accordance with the derivatives of both the Home Office Guidance on the 
Operation of Animals (Scientific Procedures) Act 1986, published by Her Majesty’s 
Stationary Office (London, UK) and the Guide for the Care and Use of Laboratory 
Animals of the National Research Council. One animal was excluded from the 
study due to mortality during the surgical procedure.  
 
Unilateral Ureteral Obstruction 
Surgical Procedure and quantification of organ injury 
This study was carried out on 23 male Wistar rats (Charles River Ltd, Margate, 
UK) weighing between 240 – 290 g and receiving a standard diet and water ad 
libitum. Animals were anaesthetized using a ketamine (150 mg/kg) (Ketaset, Fort 
Dodge Animal Health Ltd., Southampton, UK) and xylazine (15 mg/kg) (Rompun, 
Bayer Plc, Berkshire, UK) mixture i.p. (1.5 ml/kg). The abdominal fur was shaved 
and the skin cleaned with 70 % alcohol (v/v). The animals were then placed on a 
homeothermic blanket set at 37oC (Harvard Apparatus Ltd., Kent, UK). Animals 
received 0.1 mg/kg s.c. buprenorphine (0.1 ml/kg) (Vetergesic, Reckitt Benckiser 
Healthcare Ltd., Hull, UK) prior to commencement of surgery. A mid-line 
laparotomy was then performed. The right renal ureter was isolated and tied off 0.5 
cm from the renal pelvis using sterile 5-0 silk-braided suture (Pearsalls Ltd., 
Taunton, UK) following which 8 ml/kg saline at 37oC was injected into the 
abdomen and all incisions were sutured in two layers (Ethicon Prolene 5-0, Johnson 
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and Johnson, Livingstone, Scotland). Animals were then allowed to recover on the 
homeothermic blanket and placed into cages upon recovery. At the end of the 
experiment, both kidneys were removed following removal of the heart, with half 
stored in 10 % neutral buffered formalin and half snap frozen in liquid nitrogen. 
The non-ligated ureteral kidney served as sham. 
 
Experimental Design (Late Intervention) 
Rats were randomly allocated into the following groups: (i) UUO (7 days) (n=6); 
(ii) UUO (14 days) + vehicle (n=8); and (iii) UUO (14 days) + IKK16 1.0 mg/kg 
(n=9). Rats were administered vehicle (10% DMSO) or IKK16 through days 7-13 
post ureteral obstruction s.c. at a volume of 1.0 ml/kg. Contralateral kidneys of all 
groups served as ‘sham’ kidneys.  
 
Picrosirius Red Staining 
Picrosirius red staining was carried out as detailed in Chapter III. 
 
Immunohistochemistry 
Immunohistochemical staining for α-SMA and CD68+ was carried out as detailed 
in Chapter III. 
 
Western Blots 
Western blots were performed in the same fashion as described in chapter II. 
Membranes were incubated with primary antibody; rabbit anti-total IκBα (1:1000 
cat#4812 Cell Signalling Technologies, MA); mouse anti-pIκBα Ser32/36 (1:1000 
cat#9246, Cell Signalling Technologies, MA); rabbit anti-total IKKα/β (1:200, 
cat#sc-7607, Santa Cruz Biotechnology, TX); rabbit anti-pIKKα/β Ser176/180 
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(1:1000 cat#2697, Cell Signalling Technologies, MA); rabbit anti-NF-κB p65 
(1:1000 cat#8242, Cell Signalling Technologies, MA); rabbit anti-TGF-β (1:1000, 
cat#ab66043); rabbit anti-pSmad2 Ser465/467/Smad3 Ser423/425 (1:1000, cat#D27F4, 
Cell Signalling Technologies, MA); rabbit anti-Smad2/3 (1:1000, cat#D7G7, Cell 
Signalling Technologies, MA); rabbit anti-vimentin (1:1000, cat#D21H3, Cell 
Signalling Technologies, MA); rabbit anti-fibronectin (1:1000, cat#ab2413, Abcam, 
UK). The blots were then incubated with the appropriate secondary antibody 
conjugated with horseradish peroxidase (dilution 1:10000) and developed using the 
ECL detection system. The immunoreactive bands were visualized by 
autoradiography. The membranes were stripped and incubated with rabbit GADPH 
antibody (1:1000, cat#D16H11, Cell Signalling Technologies, MA) instead of β-
actin due to the involvement of β-actin the in cytoskeleton.  
 
Materials 
Unless otherwise stated, all compounds used in this study were purchased from 
Sigma-Aldrich Company Ltd. (Poole, Dorset, U.K.).  
 
Statistical Analysis 
All values described in the text and figures are expressed as mean±SEM for n 
observations. Each data point represents biochemical measurements obtained from 
up to 11 separate animals. Statistical analysis was carried out using GraphPad 
Prism 6.0b (GraphPad Software, San Diego, California, USA). Data without 
repeated measurements was assessed by one-way ANOVA followed by 
Bonferroni’s multiple-comparison post hoc test. A P value of less than 0.05 was 




The Time Course of Renal Function up to 14 days Post Unilateral Ureteral 
Obstruction 
 
The renal function of animals subject to UUO was measured before, and up to 14 
days post UUO. There was no significant change in the renal function of these 
animals at 7 or 14 days post UUO, when compared to baseline values taken 3 days 











Figure 4.1 The time course of the estimated creatinine clearance (mL/min/100g body weight) 
over a 14 day period post UUO. Each point represents n=4. Data are presented as mean ± SEM 
of n observations. 
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Effect of Late Inhibition of IKK on Sirius Red Staining in the Rat Kidney after 
Unilateral Ureteral Obstruction  
 
When compared to contralateral kidneys, kidneys subject to 14 days of UUO (+ 
vehicle) demonstrate significant increases in the % Sirius red per tissue field, 
indicating the development of fibrosis (Figure 4.2). There was no significant 
increase in fibrosis at 7 days post UUO when compared to contralateral kidneys, 
indicating the development of fibrosis from days 7-13. For this reason, I decided to 
treat the animals from days 7 – 13. Administration of IKK16 (1.0 mg/kg) on days 7 
– 13 post UUO significantly attenuated the increase in Sirius red staining for 
collagen I and III, and therefore fibrosis, when compared to vehicle treated animals 
after 14 days of UUO (Figure 4.2). Representative images of Sirius red sections are 









Figure 4.2 The time course of development of fibrosis (as measured by Sirius red for Collagen I and 
III) after unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the late 
administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO). Contralateral: n=11; 7 days post 
UUO: n=6; 14 days post UUO + 10% DMSO vehicle days 7 - 13: n=8; 14 days post UUO + 1.0 
mg/kg IKK16: n=9. Data are presented as mean ± SEM of n observations, ★P<0.05 vs. 14 days UUO 













Figure 4.3 The time course of development of fibrosis (as measured by Sirius red for Collagen I and III) 
after unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the late administration of 
IKK16 (1.0 mg/kg s.c. days 7-13 post UUO). (A) Contralateral, (B) 7 days post UUO, (C) 14 days post 
UUO + 10% DMSO vehicle days 7 – 13, (D) 14 days post UUO + 1.0 mg/kg IKK16.  
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Effect of Late Inhibition of IKK on Myofibroblast Activation in the Rat Kidney 
after Unilateral Ureteral Obstruction 
 
When compared to contralateral kidneys, kidneys subject to 14 days of UUO (+ 
vehicle) demonstrate significant increases in the % α-SMA per tissue field, 
indicating the activation of myofibroblasts (Figure 4.4). There was no significant 
increase in α-SMA staining at 7 days post UUO when compared to contralateral 
kidneys, indicating the activation of myofibroblasts from days 7-13. Administration 
of IKK16 (1.0 mg/kg) on days 7 – 13 post UUO significantly attenuated the 
increase in α-SMA staining for myofibroblasts when compared to vehicle treated 
animals after 14 days of UUO (Figure 4.4). Representative images of α-SMA 
stained sections are displayed in Figure 4.5. 
 
 
Figure 4.4 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of 
the late administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on α-SMA staining for α-
SMA-positive myofibroblasts. Contralateral: n=11; 7 days post UUO: n=6; 14 days post UUO + 
10% DMSO vehicle days 7 - 13: n=8; 14 days post UUO + 1.0 mg/kg IKK16: n=9. Data are 














Figure 4.5 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the 
late administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on α-SMA staining for α-SMA-
positive myofibroblasts. (A) Contralateral, (B) 7 days post UUO, (C) 14 days post UUO + 10% DMSO 
vehicle days 7 – 13, (D) 14 days post UUO + 1.0 mg/kg IKK16.  
 
	 133 
Effect of Late Inhibition of IKK on CD68+ staining in the Rat Kidney after 
Unilateral Ureteral Obstruction 
 
When compared to contralateral kidneys, kidneys subject to 14 days of UUO (+ 
vehicle) demonstrate significant increases in the % CD68+ per tissue field, 
indicative of macrophages (Figure 4.6). There was no significant increase in CD68+ 
staining at 7 days post UUO when compared to contralateral kidneys, indicating the 
infiltration of macrophages from days 7-13. Administration of IKK16 (1.0 mg/kg) 
on days 7 – 13 post UUO significantly attenuated the increase in CD68+ staining for 
macrophages when compared to vehicle treated animals after 14 days of UUO 
(Figure 4.6). Representative images of CD68+ stained sections are displayed in 
Figure 4.7. 
 
Figure 4.6 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of 
the late administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on CD68+ staining for 
macrophages. Contralateral: n=11; 7 days post UUO: n=6; 14 days post UUO + 10% DMSO 
vehicle days 7 - 13: n=8; 14 days post UUO + 1.0 mg/kg IKK16: n=9. Data are presented as mean 













Figure 4.7 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the late 
administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on CD68+ staining for macrophages. (A) 
Contralateral, (B) 7 days post UUO, (C) 14 days post UUO + 10% DMSO vehicle days 7 – 13, (D) 14 
days post UUO + 1.0 mg/kg IKK16.  
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Effect of Unilateral Ureteral Obstruction and the Inhibition of IKK on the NF-
κB Pathway in the Rat Kidney 
 
When compared to contralateral kidneys, kidneys subject to 14 days of UUO (+ 
vehicle) exhibited significant phosphorylation of Ser32/36 on IκBα (Figure 4.8A) 
and, hence, activation of the IKK complex (Figure 4.8B), as well as nuclear 
translocation of the p65 NF-κB subunit (Figure 4.8C). Administration of IKK16 
(1.0 mg/kg) on days 7 – 13 post UUO significantly attenuated the increase in the 
phosphorylation of IκBα on Ser32/36 (Figure 4.8A), consequently preventing the 
phosphorylation (and activation) of IKK at Ser176/180 (Figure 4.8B) and therefore the 
subsequent nuclear translocation of the p65 NF-κB subunit (Figure 4.8C) when 
compared to vehicle treated animals after 14 days of UUO. There was also a 
significant increase in Ser32/36 on IκBα (Figure 4.8A) activation of the IKK complex 
(Figure 4.8B), as well as nuclear translocation of the NF-κB subunit p65 (4.8C) in 















Figure 4.8 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the 
late administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on the activation of IκBα, IKKα/β 
and NF-κB. Activation of IκBα (A) was measured as phosphorylation of Ser32/36 on IκBα. The 
activation of IκBα results in the activation of IKKα/β, measured as the phosphorylation of IKKα/β at 
Ser176/180, which causes subsequent nuclear translocation of the p65 subunit of NF-κB (C). UUO; 
unilateral ureteral obstruction. Contralateral: n=8; 7 days post UUO: n=3; 14 days post UUO + 10% 
DMSO vehicle days 7 - 13: n=6; 14 days post UUO + 1.0 mg/kg IKK16: n=5. Densitometric analysis 
of the bands is expressed as relative optical density (OD) of IκBα phosphorylation at Ser32/36 (A) or 
IKKα/β phosphorylation at Ser176/180 (B), corrected for the corresponding total IκBα or IKKα/β 
content and normalised using the sham operated band. NF-κB nuclear translocation was evaluated by 
measuring NF-κB p65 subunit expression in both cytosolic and nuclear fractions, and expressing the 
results as nucleus/cytosol ratio. Each immunoblot is from a single experiment. Data are presented as 
mean ± SEM of n observations, ★P<0.05 vs. Contralateral, unless otherwise stated. 
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Effect of Late Inhibition of IKK on Pro-fibrotic Markers in the Rat Kidney after 
Unilateral Ureteral Obstruction 
 
When compared to contralateral kidneys, kidneys subject to 14 days of UUO (+ 
vehicle) demonstrate significant increases in TGF-β expression (Figure 4.9). There 
was no significant increase in TGF-β at 7 days post UUO when compared to 
contralateral kidneys. Administration of IKK16 (1.0 mg/kg) on days 7 – 13 post 
UUO significantly attenuated the increase in TGF-β when compared to vehicle 











Figure 4.9 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the 
late administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on TGF-β expression. 
Contralateral: n=8; 7 days post UUO: n=4; 14 days post UUO + 10% DMSO vehicle days 7 - 13: 
n=5; 14 days post UUO + 1.0 mg/kg IKK16: n=5. Densitometric analysis of the bands is expressed as 
relative optical density (OD) of TGF-β, normalised using the sham operated band. Each immunoblot 
is from a single experiment. Data are presented as mean ± SEM of n observations, ★P<0.05 vs. 
Contralateral, unless otherwise stated.  
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When compared to contralateral kidneys, kidneys subject to 14 days of UUO (+ 
vehicle) demonstrate significant increases in Smad2/3 phosphorylation (Figure 
4.10). There was no significant increase in Smad2/3 phosphorylation at 7 days post 
UUO when compared to contralateral kidneys. Administration of IKK16 (1.0 
mg/kg) on days 7 – 13 post UUO significantly attenuated the increase in Smad2/3 
phosphorylation when compared to vehicle treated animals after 14 days of UUO 













Figure 4.10 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the 
late administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on Smad2/3 phosphorylation. 
Contralateral: n=10; 7 days post UUO: n=6; 14 days post UUO + 10% DMSO vehicle days 7 - 13: 
n=6; 14 days post UUO + 1.0 mg/kg IKK16: n=6. Densitometric analysis of the bands is expressed as 
relative optical density (OD) phosphorylated Smad 2/3, corrected for the corresponding total Smad 
2/3 content and normalised using the sham operated band. Each immunoblot is from a single 
experiment. Data are presented as mean ± SEM of n observations, ★P<0.05. 
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Effect of Late Inhibition of IKK on Extracellular Matrix Proteins in the Rat 
Kidney after Unilateral Ureteral Obstruction 
 
When compared to contralateral kidneys, kidneys subject to 14 days of UUO (+ 
vehicle) demonstrate significant increases in vimentin expression (Figure 4.11). 
There was no significant increase in vimentin expression at 7 days post UUO when 
compared to contralateral kidneys. Administration of IKK16 (1.0 mg/kg) on days 7 
– 13 post UUO significantly attenuated the increase in vimentin expression when 













Figure 4.11 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the 
late administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on vimentin expression. 
Contralateral: n=6; 7 days post UUO: n=4; 14 days post UUO + 10% DMSO vehicle days 7 - 13: 
n=5; 14 days post UUO + 1.0 mg/kg IKK16: n=5. Densitometric analysis of the bands is expressed as 
relative optical density (OD) of total vimentin, normalised using the sham operated band. Each 
immunoblot is from a single experiment. Data are presented as mean ± SEM of n observations, 
★P<0.05 vs. Contralateral, unless otherwise stated. 
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When compared to contralateral kidneys, kidneys subject to 14 days of UUO (+ 
vehicle) demonstrate significant increases in fibronectin expression (Figure 4.12). 
There was no significant increase in fibronectin expression at 7 days post UUO 
when compared to contralateral kidneys. Administration of IKK16 (1.0 mg/kg) on 
days 7 – 13 post UUO significantly attenuated the increase in fibronectin 
















Figure 4.12 The effect of unilateral ureteral obstruction (UUO) at 7 and 14 days, and the effect of the 
late administration of IKK16 (1.0 mg/kg s.c. days 7-13 post UUO) on fibronectin expression. 
Contralateral: n=6; 7 days post UUO: n=4; 14 days post UUO + 10% DMSO vehicle days 7 - 13: 
n=5; 14 days post UUO + 1.0 mg/kg IKK16: n=5. Densitometric analysis of the bands is expressed as 
relative optical density (OD) of total fibronectin, normalised using the sham operated band. Each 
immunoblot is from a single experiment. Data are presented as mean ± SEM of n observations, 





Tubulointerstitial fibrosis is a major contributor to the loss of function in kidneys of 
patients with CKD, eventually leading to RRT-dependent ESRD. In this chapter, I 
have shown for the first time that the delayed inhibition of IKK, on days 7-13 in a 
rat model of UUO, resulted in a significant reduction in fibrosis and TGF-β 
expression. 
 
UUO is a popular animal model of renal fibrosis as it is relatively short-term (in 
comparison to the 5/6 nephrectomy model, for example, which takes many months) 
and therefore inexpensive, modelling tubulointerstitial fibrosis similar to that of 
human CKD. UUO is not a functional model of renal fibrosis: UUO impairs the 
function of the ipsilateral kidney, and the contralateral kidney will compensate for 
this loss of function. The measurement of biochemical markers such as SCr and 
eCCL are unchanged and renal function cannot be used as a readout for disease 
severity. I have demonstrated in this chapter that rats subject to UUO have no 
significant changes in either SCr or eCCL over a period of 14 days. Tapmeier et al. 
(2008) developed a model of murine UUO in which the ureter was re-implanted up 
to 10 days post ureteral ligation, followed by contralateral nephrectomy (Tapmeier 
et al., 2008). Post re-implantation, the inflammatory process persisted and a 
functional assessment could then be made, making this model ideal for testing 
interventions, such as IKK16, to study the reversal of fibrosis, reduction of 
inflammation and/or the restoration of renal function. This model, however, is 
technically challenging due to the micro-suturing required to re-implant the ureter 
back into the bladder of the mouse.  
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In this chapter vehicle treated animals exhibit a significant increase in renal fibrosis 
when compared to contralateral (unligated) kidneys at 14 days post UUO, via the 
measurement of Sirius red staining for collagen I and III. At 7 days post UUO, 
there was no significant increase in any parameters associated with fibrosis 
(increased collagen I/III, increased α-SMA). Knowing that the development of 
fibrosis in this model occurred between 7 and 14 days post UUO, I decided to treat 
the animals in this period. The late inhibition of IKK (on days 7 – 13 s.c.) by 
IKK16 successfully reduced renal fibrosis caused by UUO.  
 
In this chapter, I have demonstrated that the administration of IKK16 at days 7 – 13 
significantly attenuates UUO-dependent increases in α-SMA, fibronectin and 
collagen I and III (as measured by Sirius red staining). Similarly, previous studies 
have demonstrated that IKK inhibition suppresses α-SMA and fibronectin 
expression as well as collagen type I production in dermal myofibroblasts via 
diminished nuclear translocation of NF-κB (Mia and Bank, 2015). I have shown 
here that the inhibition of IKK during days 7-13 post UUO reduces IKK activation 
and translocation of the NF-κB p65 subunit. The expression of the NF-κB p65 
subunit and its nuclear translocation may be stimulated by TGF-β (Sun et al., 
2015). Sun et al. (2015) described the increase in the p65 subunit in lung fibroblast 
differentiation when stimulated by TGF-β in vitro, and a further knockdown of 
Smad3 inhibited the TGF-β induced NF-κB p65 expression (Sun et al., 2015). In 
addition, NF-κB antisense oligonucleotide inhibits acquisition of the myofibroblast 
phenotype in lung fibroblasts after challenge with bleomycin (Zhou et al., 2014). 
TGF-β, therefore, may be important for the induction and translocation of NF-κB in 
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fibrosis, and NF-κB in turn may induce the myofibroblast phenotype (an increase in 
α-SMA) in renal fibroblasts.  
Further to this, I have demonstrated that after 14 days post UUO, kidneys subject to 
UUO in vehicle treated animals exhibit a significant increase in staining for CD68+, 
indicative of macrophages. After UUO, recruited macrophages are polarized from 
M1 (a subset whose functions include the removal of dead cells and debris) to M2 
macrophages, which have the ability to stimulate tissue repair (Wang et al., 2015). 
M2 macrophages produce TGF-β1 to suppress bone morphogenetic protein 7 
(BMP7), encouraging EMT. Depletion of M2 macrophages in UUO inhibits EMT 
and consequent fibrosis, however the same effect is not seen with M1 depletion 
(Pan et al., 2015). In various models of renal fibrosis, ablation of macrophages 
causes a considerable reduction in fibrosis (van Goor et al., 1992). Therefore, 
during chronic injury, prolonged infiltration of M2 macrophages may promote renal 
fibrosis (Pan et al., 2015).  
 
I have shown here, for the first time, that the inhibition of IKK on days 7-13 post 
UUO resulted in a significant reduction in the staining for CD68+, in kidneys 
subject to UUO when compared to vehicle-treated animals. Target genes of NF-κB 
include MCP-1, a monocyte chemoattractant (Guijarro and Egido, 2001). Inhibition 
of NF-κB with curcumin reduces MCP-1 expression, resulting in a reduction in 
immunostaining for macrophages (Kuwabara et al., 2006). Zhang et al. (2009) have 
described an increase in monocyte recruitment in vascular smooth muscle cells 
after vascular injury, through the activation of Smad2/3 and consequent gene 
transcription of MCP-1 (Zhang et al., 2009). Furthermore, overexpression of Smad 
3 caused significant increases in MCP-1 and therefore monocyte recruitment 
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(Zhang et al., 2009). Moreover, neutralisation of MCP-1 in a mouse model of 
crescentic glomerulonephritis (producing a progressive fibrosis) dramatically 
reduced macrophage infiltration (by 47%) and collagen I (by 65%) when compared 
to untreated mice with crescentic glomerulonephritis (Lloyd et al., 1997). The 
increase in macrophage infiltration in animals subject to 14 days of UUO (+ 
vehicle) presented in this chapter, may therefore be due to the increase in TGF-β 
and Smad 2/3 signalling, and therefore increased MCP-1 gene transcription after 14 
days of UUO (Zhang et al., 2009). IKK16 treated animals subject to UUO 
demonstrated a reduced macrophage infiltration when compared to vehicle control 
animals. It is possible that the inhibition of IKK, and a consequent inhibition of NF-
κB translocation may prevent or reduce transcription of MCP-1, causing a reduction 
in macrophage influx into the renal tissue, however this is something I have yet to 
measure. Further experiments to explore MCP-1 expression would provide a 
greater insight into the mechanism of IKK-dependent macrophage activity. 
In addition, macrophage-produced TGF-β1 causes local activation of 
myofibroblasts and EMT of tubular epithelial cells (Sutariya et al., 2016). These 
cells in turn produce their own source of TGF-β1, responsible for the production of 
ECM including fibronectin and vimentin. Mice over-expressing TGF-β1 develop 
renal fibrosis (Schnaper et al., 2003). Therefore, in this chapter, the reduction in 
TGF-β in IKK treated animals results in an attenuation of collagen I + III and ECM 
production (Sato et al., 2003). TGF-β binding TGF-β receptors activates Smads 2/3 
to promote the production of pro-fibrotic genes. Smad3 -/- mice subject to UUO are 
protected against renal fibrosis, exhibiting reduced collagen, monocyte influx and 
reduced EMT, as Smad 3 is essential for TGF-β1-stimulated EMT (Sato et al., 
2003). UUO caused a significant increase in the phosphorylation of Smad 2/3 at 
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day 14, which was successfully attenuated by the administration of IKK16 on days 
7-13 post UUO. As Smad 2/3 is phosphorylated through TGF-β binding to the 
TGF-β receptor complex, attenuation in Smad 2/3 phosphorylation is due to 
reduced TGF-β receptor binding after IKK inhibition. 
 
Finally, 14 days of UUO (+ vehicle) caused a significant increase in vimentin 
expression. Other than its role as an intermediate filament, vimentin is expressed in 
cells of mesenchymal origin and is used as a marker for EMT (Dave and Bayless, 
2014). The western blots for vimentin in this chapter indicate that the vimentin has 
been ‘cleaved’ as there are two bands, one clear band at 56kDa (‘normal’ 
vimentin), and longer band at a lower molecular weight (‘cleaved vimentin’). 
Intermediate filaments, including vimentin, can be cleaved and dismantled by 
various proteases, including calpain (Yoshida et al., 1984) and cysteine-dependent 
aspartate-directed proteases (caspases) (Byun et al., 2001). Caspases are a family of 
proteases that mediate apoptosis. Further to this, caspases 3 and 7 cleave vimentin 
at Asp85 producing a 48kDa fragment of vimentin (Byun et al., 2001), and caspase 
6 to cleave vimentin at Asp259 producing lower molecular weight fragments from 
20-30kDa (Byun et al., 2001). The cleavage of vimentin is initiated in apoptosis 
after caspase activation, and as there is strong evidence for the presence of 
apoptosis in UUO (Chevalier et al., 2009), this may provide an explanation for the 
cleavage of vimentin in both vehicle treated and IKK16 treated animals after 14 
days of UUO in this chapter. Further experiments are required to assess the 
cleavage of vimentin and how it was reduced in IKK16 treated animals when 
compared to vehicle treated animals after 14 days of UUO. Further experiments 
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such as the study of caspase activation in UUO are required to further understand 
whether this is responsible for the cleavage of vimentin in this model.  
 
In the UUO study I performed, rather than inhibiting IKK during the initial 
inflammatory stage (the first 7 days), I instead treated rats during the stage of 
collagen deposition and myofibroblast formation (the last 7 days). For the first time, 
I have identified that the late treatment of UUO with IKK16 prevents the deposition 
of collagen via reduction in TGF-β expression and formation of myofibroblasts, 
suggesting that the activation of IKK continues to be a critical component during 






















AKI continues to be a great burden for the National Health Service, costing an 
estimated £500 million per annum (NHS Kidney Care, 2012). This figure is 
continually rising, due to the large increase in the number of patients suffering from 
AKI. Up to 7% of hospitalized patients present with AKI, and of these 7%, up to 
60% will never regain full renal function (Uchino, 2006). Following AKI, a 
majority of patients will go on to later develop CKD, and with the increasing 
incidence of CKD comes an increase in ESRD, significant increases in treatment-
associated costs and a large mortality rate (>1 million people per annum) (Hamer 
and El Nahas, 2006). 
 
In this thesis, I have used a rat model of unilateral renal IRI (with contralateral 
nephrectomy). The literature contains models of both unilateral and bilateral renal 
IRI in a variety of species, most commonly rat or mouse. I chose the unilateral 
model of renal IRI as contralateral nephrectomy eliminates compensation of 
contralateral kidneys (as in the bilateral model of renal IRI) and, therefore, 
minimises variation in functional results (Skrypnyk et al., 2013). In the clinical 
setting, AKI may occur during or after transplantation in the recipient (Rao and 
Kjellstrand, 1983), and nephrectomised rats develop proteinuria, 
glomerulosclerosis, tubulointerstitial fibrosis and renal dysfunction after many 
months (Polichnowski et al., 2014). This is associated with the progression to CKD 
later in both pre-clinical models and in clinical studies (Nehus and Devarajan, 
2012): another reason for using the unilateral renal IRI model. Previous 
publications by Thiemermann and colleagues have used a rat model of 30 min 
bilateral renal ischaemia and 48 h reperfusion, demonstrating significant renal and 
glomerular dysfunction (Patel et al., 2012). I adopted the same method, substituting 
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only the bilateral ischaemia for a unilateral ischaemia with contralateral 
nephrectomy.  
In chapter II of this thesis, unilateral IRI with contralateral nephrectomy caused a 
significant increase in renal dysfunction, as measured by serum urea, glomerular 
dysfunction as measured by SCr and the eCCL and tubular dysfunction as measured 
by the FENa+. All of these parameters were reversible, indicating an acute insult 
similar to that of human AKI. Serum urea is one of the most widely used tests for 
kidney function in the clinical setting and is elevated post AKI: as I have shown in 
animals subject to renal IRI in chapter II of this thesis. FENa+ is useful in AKI 
evaluation: a high FENa+ represents Na+ loss and therefore tubular damage, which 
is useful in the diagnosis ATN or intrinsic renal failure.  
In patients, AKI is diagnosed as a rise in SCr occurring between 24 and 72 h post 
AKI, a major flaw in the clinical diagnosis process as nephron damage occurs 
before this period. Both serum urea and SCr may also be affected by factors not 
relating to AKI, highlighting the need for early detection of injury with biomarkers, 
such as troponin in myocardial ischaemia. Measurement of early renal biomarkers 
requires further development and refinement: the ideal biomarker would predict 
long term outcomes such as mortality and potential CKD development as well as 
short term outcomes such as dialysis post AKI. Biomarkers such as NGAL and 
kidney injury molecule-1 (KIM-1) are highly sensitive and renal-specific but have 
not yet been developed for clinical use. However, despite the need for the earlier 
detection of AKI, I have shown here for the first time that it is possible to treat 
animals subject to renal IRI at peak SCr (24 h), demonstrating that a clinically 
relevant treatment strategy in relation to SCr elevation is possible. 
 
	 150 
There is good evidence that NF-κB plays a detrimental role in renal IRI. In this 
thesis, I have demonstrated that kidneys of rats subject to 30 min/48 h renal IRI, the 
activation of NF-κB is significantly elevated compared to sham animals. Similar 
data by Patel et al. (2012) demonstrates an increased p65 NF-κB nucleus to cytosol 
ratio at 48 h post reperfusion after 30 min bilateral renal IRI (Patel et al., 2012). 
Further to this, the phosphorylation of IκBα (this thesis) was also elevated at 48 h 
post reperfusion. With these data in mind, I treated the animals at 24 h post 
reperfusion at peak SCr and prior to NF-κB activation. In this thesis, I have 
demonstrated for the first time that the delayed inhibition of IKK (at 24 h), using 
the IKK inhibitor IKK16, in a rat model of unilateral renal IRI and contralateral 
nephrectomy attenuates IRI-dependent changes in biochemical markers (namely 
serum urea, SCr, eCCL and FENa+), indicating improvement in renal, glomerular 
and tubular function when compared to control animals. In addition, IKK inhibition 
(at 24 h) successfully attenuated IκBα phosphorylation and consequent NF-κB 
translocation to the nucleus.  
NF-κB mediates many inflammatory states, including AKI, playing a fundamental 
role in the production of pro-inflammatory cytokines such as IL-6, IL-1β, and IL-8, 
to name a few (Bonizzi and Karin, 2004). It has previously been proven that the 
early inhibition of NF-κB in inflammatory disease states successfully attenuates 
inflammation. López-Franco et al. (2002) have previously shown that in an animal 
model of glomerulonephritis, early NF-κB inhibition reduced proteinuria, 
glomerular lesions and monocyte/macrophage infiltration (López-Franco et al., 
2002). The inhibition of IKK at 24 h post reperfusion most likely reduced IRI-
associated inflammation, restoring both functional and structural injury to sham-
like levels.  
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Figure 5.1 The structure of 
IKK16, a 2-benzomido-
pyrimidine, with selectivity for 
IKKβ. Taken from (Waelchli et 
al., 2006) 
The compound used in this thesis, IKK16, was 
screened from a Novartis compound archive for ‘hits’ 
with a typical kinase inhibitor motif (Figure 5.1) 
(Waelchli et al., 2006). IKK16 is a tertiary 2-
benzamido-pyrimidine with selectivity for IKKβ, and 
of all the compounds screened in this paper, IKK16 
was the most potent. This was confirmed by an IκBα 
degradation assay, from which the IC50 value was 
calculated (Waelchli et al., 2006). IKK16 was among 
several compounds tested and was further used in in vivo efficacy studies. Firstly, 
IKK16 was used in a rat model of lipopolysaccharide (LPS)-induced TNF-α 
release, where both p.o. (30 mg/kg) and s.c. (30 mg/kg) IKK16 administered 1 h 
prior to LPS challenge produced a significant attenuation of plasma TNF-α, and 
inhibited the expression of adhesion molecules E-selectin, ICAM and VCAM 
(Waelchli et al., 2006). In a second animal model, IKK16 (10 mg/kg s.c.) inhibited 
neutrophil extravasation in thioglycollate-induced peritonitis (Waelchli et al., 
2006). 
 
Previous in vivo studies by Waelchli et al. (2006) administered 30 mg/kg IKK16 via 
p.o. and s.c. routes of administration (Waelchli et al., 2006), so the decision was to 
lower the dose based on a i.v. route of administration, with a dose response from 
0.1 mg/kg to 1.0 mg/kg. I demonstrate in this thesis that the two lowest 
concentrations of IKK16 (0.1 mg/kg and 0.3 mg/kg) administered at 24 h post 
reperfusion had no significant effect on any of the biochemical parameters 
measured (serum urea, SCr, eCCL and FENa+). Assuming a blood volume of 
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17.5ml per 250 g rat, 0.1 mg/kg and 0.3 mg/kg would result in a plasma 
concentration of approximately 2.75 µM and 9.15 µM, respectively. The IC50 
values for IKK16 are as follows: IKKβ, 40 nM; IKK complex, 70 nM; IKKα, 200 
nM. Despite the calculated plasma concentrations for both 0.1 mg/kg and 0.3 mg/kg 
being sufficient to inhibit the IKK complex, the plasma concentration of IKK16 
will realistically be lower than this for two reasons: 1) tissue distribution of the 
compound and 2) elimination of the compound by metabolism or excretion. 
Pharmacokinetic studies are required to determine the half-life of the compound 
and the concentration of IKK16 in the kidney after administration. IKK16 may 
have a short pharmacodynamic profile that may result in a reduced plasma 
concentration. Based on the assumptions previously described, 1.0 mg/kg would 
result in a plasma concentration of 27.5 µM, likely to result in a sufficient plasma 
concentration to inhibit IKK. 1.0 mg/kg IKK16 successfully inhibited the IKK 
complex (as demonstrated in chapter II by the attenuation of renal IRI-dependent 
increases in the phosphorylation of Ser176/180 on IKK and therefore its activation, 
and further confirmed by the attenuation of the phosphorylation of Ser32/36 on IκBα 
and the p65 NF-κB nucleus to cytosol ratio).  
 
I decided to use IKK as a target, as it is just upstream from NF-κB. The debate 
surrounding NF-κB inhibition is very much a ‘hot’ topic and the dilemma 
surrounding when to inhibit NF-κB is still being elucidated given that more than 
800 synthetic and naturally occurring compounds partly mediate their effects 
through the modulation of NF-κB activation (Gilmore and Herscovitch, 2006). I 
propose that the initial activation of NF-κB for the onset of inflammation is critical 
for the induction of subsequent tissue-repair mechanisms by a complex system of 
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gene expression for molecular regulators such as various growth factors, adhesion 
molecules and cell cycle regulators. It is the over-activation of NF-κB that must be 
limited in order to allow such tissue-repair mechanisms to be initiated. 
 
The use of knockout animals would help to further elucidate the role of IKK in 
renal IRI and the development of fibrosis. IKK-/- animals die in utero; IKKα-/- 
animals die shortly after birth, and display defective keratinocyte differentiation 
and skeletal abnormalities (Sil et al., 2004), whereas IKKβ-/- mice experience liver 
injury and apoptosis during embryonic development around day 14 (Tanaka et al., 
1999). A similar phenotype is seen with IKKγ knockout animals, which are also 
embryonically lethal (Rudolph et al., 2000). Despite this, conditional deletion of 
IKKβ is possible via cre-loxP technology. In a mouse model of stroke, IKKβ gene 
deletion by crossing mice carrying Ikbkb alleles flanked by loxP sites markedly 
reduced ischaemic death in neuronal cells (Herrmann et al., 2005). Again, this 
technique could be used to further confirm the role of IKK in both renal IRI and the 
subsequent development of fibrosis.  
 
Recent clinical research has highlighted the dramatic link between AKI severity 
and progression to CKD (Belayev and Palevsky, 2014). In chapter III of this thesis, 
I extended the reperfusion period to 28 days following unilateral renal IRI (with 
contralateral nephrectomy), to simulate the development of CKD. The extension of 
the renal IRI model did not result in a reduction in renal function as seen in CKD 
patients post AKI, however after excision of the kidney, it was found that there was 
significant development of fibrosis in vehicle-treated rats. Furthermore, this was 
ameliorated by the inhibition of IKK with one single bolus of IKK16, at 24 h post 
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reperfusion, at peak SCr. Basile et al. (2015) have recently described repair after 
AKI as ‘adaptive’ or ‘maladaptive’ (Basile et al., 2015). Adaptive repair describes 
the return of ‘normal’ structure and function at 90 days post AKI, characterised by 
rapid restoration of renal function, proliferation of tubular cells, and resolution of 
pathology, inflammation and damage biomarkers (Figure 5.2A). Conversely, 
maladaptive repair consists of a reduction in kidney function associated with a 
change in renal structure, expression of pro-fibrotic factors, delayed resolution of 
inflammation and damage biomarkers (Figure 5.2B) (Basile et al., 2015). 
Maladaptive repair occurs within the tubules, vasculature and the interstitial space 
post AKI, therefore promoting the deposition of collagen in the interstitium. Figure 
5.2 demonstrates these types of repair, and suggests that the repair in this chapter 
may be either adaptive or maladaptive, due to the restoration of original renal 
function 7 days post renal IRI (adaptive) and the persistence of pro-fibrotic markers 
at day 28 (maladaptive). For future studies, modelling more severe maladaptive 
repair may be more suitable due to the development of permanent fibrosis and a 
persistent decline in renal function. It is the balance between these two repair states 
that predicts fibrosis and CKD development. In clinical situations, the probability 
of progressing to CKD from AKI increases proportionally with the number of 
episodes of AKI (Belayev and Palevsky, 2014); therefore future work to develop an 
animal model to include multiple sessions of renal IRI in vivo may be of more 
clinical relevance. Delivering more severe injury to promote fibroblast activation, 
fibrosis development and functional decline would provide a more accurate model 
to study the AKI to CKD phenomena, and indeed the inhibition of IKK. 
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I have demonstrated for the first time that the inhibition of IKK at peak SCr not 
only reduces both structural and functional injury at 48 h post reperfusion, but also 
surprisingly causes a significant reduction in fibrosis at 28 days post reperfusion 
when compared to control animals. I have further found a significant increase of 
TGF-β and α-SMA at 7 days post reperfusion in vehicle treated animals. This data 
indicates the beginning of the fibrotic process in this model, however may also be 
used as a timeline of when to use certain compounds to target fibrosis, e.g. the 
administration of a TGF-β inhibitor at 7 days post IRI. Studying activation of 
particular markers at different times in the progression may open a whole new door 
to accurate initiation of therapies to combat impending CKD. Clinically, it is 
difficult to know when to intervene, what to intervene with, and when previous 
episodes of AKI have occurred. Such issues require a better understanding of 
biomarkers involved in the progression of AKI to CKD, and better animal models 
to deal with this.  
A B 
Figure 5 Clinical AKI with (A) adaptive and (B) maladaptive repair. Adaptive repair is injury causing 
an increase in both damage and functional markers, in which repair matches injury and therefore 
resolution of AKI. Maladaptive repair sees injury levels higher than repair rate and therefore fibrosis is 




Fibrotic disease is responsible for 45% mortality in the developed world (Wynn, 
2008), and yet there are still no effective, approved anti-fibrotic treatments. Finally, 
in chapter IV of this thesis, I have demonstrated that the inhibition of IKK on days 
7-13 in a rat UUO model successfully attenuated renal fibrosis formation, 
myofibroblast activation and macrophage infiltration. Previous studies inhibiting 
IKK in a variety of different animal models of lung (Ogawa et al., 2011), liver (Wei 
et al., 2011) and heart (Maier et al., 2012) have proven the importance of the role of 
IKK in the fibrotic process. In reality, treating fibrosis in patients is likely to be far 
more complex than the sole inhibition of IKK; fibrosis involves multiple 
interconnecting pathways, each molecule playing a similarly important role to the 
next. Realistically, inhibition of a single pathway in the fibrotic process will not 
sufficiently completely eradicate/halt fibrosis, therefore in future, combination 
therapies targeting multiple pathways should be considered. 
 
In conclusion, it is evident that NF-κB and the activation of IKK affect functional 
and structural outcomes after both renal IRI and the subsequent development of 
fibrosis. In this thesis, I have mapped the time course of NF-κB in an acute model 
of renal IRI, finding the inhibition of IKK at 24 h post reperfusion to be of both 
functional and structural benefit to the kidney. The successful inhibition of IKK at 
peak SCr demonstrates that it is possible to intervene in patients with AKI at such a 
late stage (i.e. peak SCr), providing hope for the development of such therapies. 
Furthermore, the amelioration of functional and structural damage via the inhibition 
of IKK at 24 h successfully ameliorates the subsequent development of fibrosis, 
pro-fibrotic markers and over-production of ECM components at 28 days post renal 
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IRI. In addition, the inhibition of IKK in a model of UUO, modelling 
tubulointerstitial fibrosis, successfully attenuates the production of fibrosis, pro-
fibrotic markers and over-production of ECM components after 14 days of UUO. 
These data indicate that the activation of the IKK complex drives tubulointerstitial 
fibrosis, and suggests that the inhibition of IKK could be a useful pharmacological 
tool for the creation of therapies to combat AKI and the subsequent development of 
fibrosis, via the reduction of both inflammation and the prevention of the 




















Suggestions for Future Research 
	
	
• To measure early damage biomarkers (such as KIM-1, cystatin C, NGAL) in 
the rat model of renal IRI (30 min ischaemia/28 day reperfusion) throughout the 
timecourse, to assess whether the development of fibrosis in vehicle control 
animals correlates with biomarker expression at any time point. If so, does the 
inhibition of IKK with IKK16 reduce biomarker expression?	
• To extend the reperfusion period (after 30 min ischaemia) to 90 days to assess 
whether the fibrosis developed in vehicle control animals reverses, persists or 
worsens, and to see the effect that IKK inhibition (at 24 h post reperfusion) has 
on fibrosis in the kidney after a 90 day reperfusion period.	
• To develop a new rat model of unilateral renal IRI (45-60 min) with no 
contralateral nephrectomy. The renal function will remain sham-like in injured 
animals due to the functioning contralateral kidney; however, this model would 
deliver a more severe renal insult, resulting in a more severe fibrosis, and may 
also result in persistent myofibroblast activation and macrophage infiltration at 
28 days. Additionally, this model could be used to see whether the inhibition of 
IKK with IKK16 at 24 h post reperfusion causes a reduction in renal fibrosis 
developed at 28 days post renal IRI.	
• To investigate the activation of other transcription factors post renal IRI in the 
rat, e.g. peroxisome proliferator-activated receptor-γ (PPAR-γ). PPAR-γ 
agonism prior to, and during reperfusion, has shown to be beneficial in renal 
IRI (Sivarajah et al., 2003).  Many insulin-sensitizing drugs target PPAR-γ and 
are already approved as pharmacological therapies for type II diabetes. Using 
therapies already approved for human use in pre-clinical studies therefore 
increases the translatability of the intervention (if successful in renal IRI). 	
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Conclusions 
• In the first chapter of this thesis, I studied the timecourse of AKI in a rat model 
of IRI (30 minutes ischaemia, 24, 48 and 72 h reperfusion). During the time 
course, renal dysfunction (maximal SCr) was most significant at 24 h post 
reperfusion, and NF-κB activation was at 48 h post reperfusion. Using these 
data I treated animals at 24 h post reperfusion with the IKK inhibitor, IKK16. 
• IKK inhibition at 24 h post reperfusion successfully attenuated renal 
dysfunction and histological changes associated with AKI, whilst also inhibiting 
IKK activation and subsequent NF-κB translocation. These data indicate that 
renal IRI may be successfully treated at 24 h post reperfusion, during peak SCr, 
at which time AKI is diagnosed. This may be a step forward into research 
aimed at therapy initiation post-AKI diagnosis. 
• Furthermore, IKK inhibition at 24 h post renal IRI successfully reduced the 
development of fibrosis associated with 30 min ischaemia and 28 days of 
reperfusion in a rat model of IRI. IKK inhibition also reduced the activation of 
myofibroblasts and the infiltration of macrophages at 7 days post reperfusion. 
This indicates that the early amelioration of AKI post-diagnosis may 
reduce/retard/prevent the development of fibrosis and therefore the progression 
to CKD after AKI. 
• IKK inhibition also reduced fibrosis development, myofibroblast activation and 
macrophage infiltration associated with UUO. 
• These data indicate that the activation of the IKK complex drives fibrosis, and 
suggests that the inhibition of IKK could be a useful pharmacological tool for 
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